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In respectful memory of Luca, 
Whose battle was prematurely halted: 
May his courage be an example for us all, 
Facing the darkest nights with serenity and glee.  
We all miss you.   
 
Abbreviations 
KTx  kidney transplant 
KTR  kidney transplant recipient 
ESRD  end stage renal disease 
CKD  chronic kidney disease 
U-prot  urinary proteins 
DGF  delayed graft function 
IS  immunosuppressive 
CNI  calcineurin inhibitor 
mTORi mammal Target Of Rapamycin inhibitor 
CyA  Cyclosporine A 
Tac  Tacrolimus 
MMF  Mycophenolate 
Aza  Azathioprine 
Rapa  Sirolimus 
Ever  Everolimus 
ATG  anti-thymocyte globuline 
BPAR  biopsy proven acute rejection 
DSA  donor specific antibody (anti-HLA mismatches) 
PTDM  post transplant diabetes mellitus 
T2DM  type 2 diabets mellitus 
PTLD  post transplant lymphoproliferative disorder 
MACE major adverse cardiovascular event 
SNP  single nucleotide polymorphism 
OR  odds ratio 
HR  hazard ratio 
95%CI  95% confidence interval 
HPV  human papilloma virus 
HPyV  human polyoma virus 






Complications of Kidney Transplant 
Kidney transplant (KTx) is the therapy of choice of end stage renal disease (ESRD), assuring a 
better and longer life than other renal replacement therapies (RRT). However –to date- KTx 
recipients (KTR) need a chronic antirejection therapy with immunosuppressive drugs (IS), 
which cannot be withdrawn to maintain a stable graft function.  
Moreover most KTRs have some degree of chronic kidney disease (CKD) because only one 
kidney is transplanted, it is perfused from the iliac artery (smaller than abdominal aorta) and 
most of them develop a chronic rejection which impairs over time the kidney function. 
Lastly they often have metabolic anomalies which pathogenesis has not been elucidated: the 
major hypothesis claim as culprits the chronic inflammation due to chronic rejection, rapid 
changes in the diet (from dialysis to KTx), IS drugs (like steroids) and long term alterations 
persisting after the ESRD phase. 
Indeed KTRs have a lower life expectancy than the general population, mainly due to 
cardiovascular events, severe infections and malignancies. Moreover KTRs as a population are 
a “sick” population with a very high morbidity despite a relatively normal lifestyle and social 
rehabilitation. Interestingly these characteristics have dramatically reduced the resources 
devoted to the development of novel IS agents, as pharmaceutical company front-men say: 
“they [novel IS] all fail to achieve better outcomes than standard IS and get too many side 
effects, even if they are not likely to be related to the study drug”. Therefore, research and 
development of IS are now targeting different “immunological” population, like multiple 




Cardiovascular disease is a leading cause of morbidity and mortality after KTx, accounting for 
50-60% of post-transplant deaths. For instance the incidence of ischemic heart disease of 
approximately 1 per 100 person-years at risk.  
The high rate of cardiovascular deaths in the transplant population is due in part to the large 
number of diabetic patients receiving a KTx and to KTR who develop post-transplant diabetes 
(PTDM). However, the cardiovascular risk among non-diabetic KTR is still higher than in the 
general population, due to both an exacerbation of traditional risk factors by IS drugs (Figure) 
and to nontraditional risk factors related to both IS and CKD. 
 
Figure. Potential interactions between IS drugs and “classical” and “non-classical” risk 
factors for CVE in kidney transplant recipients. 
 
Traditional risk factors for major adverse cardiovascular events (MACE) include previous 
events, patient age, diabetes mellitus, male sex, hypertension and dyslipidemia. However the 
Framingham risk score greatly underestimates the risk of cardiovascular events among KTRs. 
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Although the individual Framingham risk factors are significantly associated with 
cardiovascular risk among KTRs, the effect sizes are increased among such patients, especially 
among patients at high risk. 
Nontraditional risk factors that have been associated with increased cardiovascular risk in 
various studies include reduced kidney function following transplantation, dialysis vintage 
prior to transplantation, rejection, hyperhomocysteinemia, elevated levels of lipoprotein(a), 
elevated C-reactive protein and interleukin-6 levels, reduced homoarginine levels, proteinuria, 
and low levels of physical activity. Although not directly linked to cardiovascular disease, the 
presence of vascular calcifications detected radiographically prior to transplantation (a 
common finding) is also associated with increased cardiovascular and all-cause mortality 
posttransplantation. 
Among MACEs, myocardial infarction may be a fatal event and is relatively common: among 
nearly 36,000 patients (USRDS data), the incidence of myocardial infarction at 6, 12, and, 36 
months was 4.3%, 5.2%, and 11.1% respectively. KTx-related risk factors are older and 
deceased donors (worse post-KTx renal function), delayed graft function (DGF), PTDM, a 
failing graft, and previous vascular disease. 
Even if not fatal, myocardial infarction may result in congestive heart failure (CHF), which is 
in the US the second most common cause of hospitalization of KTRs, having a cumulative 
incidence of 18.3% at 3 years after surgery. Independent risk factors for new-onset CHF after 
transplantation include age, diabetes, anemia, hypertension, obesity, and suboptimal graft 
function. 
Interestingly an increasing dialysis vintage prior to transplantation is associated with a graded 
increase in the risk of cardiovascular death after KTx. A likely explanation for this is that 
accelerated atherogenesis is observed as part of the uremic syndrome. Proatherogenic factors 
that contribute to the progression of vascular disease prior to transplantation may include 
hyperhomocysteinemia, hyperfibrinogenemia, increased calcium ingestion, abnormalities of 
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mineral metabolism, dyslipidemia, and modification of low-density lipoproteins (LDL) by 
advanced glycosylation end-products (AGE), particularly in diabetic patients, but also in non-
diabetic patients. These same factors become increasingly important with the onset of chronic 
allograft dysfunction that leads to progressive uremia. 
Indeed, only one model(by Soveri et al) has been validated to predict the risk of MACE in 
KTRs and includes some “Framingham” variables, as well as the mostly associated “KTx-
associated” variables. 
 
Table. Model by Soveri et al (Transplantation 2012) predicting the 7-year cumulative incidence of 
major cardiovascular events (MACE) and death in kidney transplant recipients. In the original 
paper the AUC of these models in the assessment and test samples was 0.735-0.740 and this model was 
validated in the BENEFIT and BENEFIT-EXT populations. 




Diabetes Mellitus 2.21 1.91 










Coronary heart disease 1.97 1.32 
# of Transplants 1.40 - 
Total time on RRT (per 5 years) - 1.02 
Creatinine (per 1 mg/dL) 1.52 1.50 
Age (per 10 year) 1.51 1.75 
“Standard” 7-years cum. incidence * 3.1% 6.74% 
* no risk factors, age=50 years, Creat=1.0 mg/dL, LDL=1 mmol/L, first transplant, 1-year on RRT 
 
At the end of the day, the reduction of cardiovascular risk requires an accurate assessment of 
risk in KTRs (which is not ease achieved) and the appropriate pharmacologic and 
nonpharmacologic interventions. Particularly there is considerable practice variation in the use 
of potentially cardioprotective medications in KTR, even among patients considered to be at 
high risk. Studies suggest that primary and secondary cardiovascular preventive measures 
(aspirin and lipid-lowering drugs) are underutilized among transplant recipients, probably 
because their utility is far from being proven in this population. For example the Long-Term 
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Deterioration of Kidney Allograft Function (DeKAF) study revealed that fewer than 60% of 




Body mass index (BMI) was independently associated with CHF in several USRDS registry 
studies. In one study, BMI greater than or equal to 30 predicted up to 59 percent relative risk 
increase, compared with BMI less than 30. In another study of USRDS data, BMI greater than 
28.3 independently predicted a 57 percent relative increase in the risk of hospitalized CHF, 
compared with lower BMI. 
A portion of obesity-related cardiovascular risk may be mediated by impacts on metabolic 
health including diabetes. A meta-analysis of six studies including 4111 patients demonstrated 
an increased risk of post-transplant diabetes (PTDM) associated with BMI >30 compared with 
<30 kg/m2 (pooled risk ratio 2.24, 95% CI 1.46-3.45). 
Obesity trends in transplant recipients tend to mimic the general population: from the data of 
the United Network for Organ Sharing, among 27,372 individuals who underwent kidney 
transplantation between 1997 and 1999, 20% were obese (BMI>30), and an additional 30% 
were classified as overweight (BMI 25 to 29). 
Moreover, weight gain after transplant is common and may be related to improved appetite 
with reversal of uremia and relatively high steroid doses in the peritransplant period, but is also 
associated with physical inactivity. 
Obesity among transplant recipients is frequently associated with the metabolic syndrome. 
Obesity increases the risk of cardiovascular disease in the general population; among kidney 
transplant recipients, the presence of obesity, particularly in association with the metabolic 
syndrome, also appears to be associated with an increased number of adverse cardiovascular 
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events. In one study of 337 renal transplant recipients, one-third had metabolic syndrome by 
the first transplant anniversary, whereas only 20 percent had metabolic syndrome before 
transplant. Over eight years of follow-up, 42 percent of the sample developed atherosclerotic 
disease events, and the risk of these events was significantly increased among patients with 
metabolic syndrome by one year after transplant (HR 3.4, 95% CI 1.6-7.3). 
High BMI has also been associated with an increased risk of cardiac death after kidney 
transplantation. In a study of nearly 52,000 patients in the USRDS registry, the adjusted risk of 
cardiac death increased at both low BMI (aHR 1.3 for BMI <20) and high BMI (aHR 1.2 for 
BMI 30 to 32; aHR 1.4 for BMI >36), compared with the reference group with BMI 22 to 24. 
Lifestyle changes based in diet and exercise, with supervision by a renal dietician as needed, 
are first-line strategies to achieve and maintain normal body weight among obese transplant 
recipients. Cases of bariatric surgery among morbidly obese transplant recipients have been 




It has been known for many years that solid organ transplant recipients are at higher risk of 
cancer at most sites. Cancer is a major cause of morbidity after transplantation, with up to one-
third of deaths with a functioning allograft due to cancer. Still, with an aging transplant 
population the presence of additional co-morbidity is increasingly common, and so, in aiming 
to optimize long-term patient outcomes, clinicians’ advice must balance the prospect of graft 
failure and dialysis, with competing risk of diabetes, cardiovascular and cerebrovascular 





A large body of evidence, however, indicates that the chronic use of immunosuppressive drugs 
is associated with increased risks of opportunistic diseases, particularly cancers. After 10 years 
of immunosuppression, KTRs have a cumulative incidence of cancer as high as 20%. As 
compared to the age- and sex- matched general population, a 3-to-5-f old increased risk was 
documented, among KTR, for NMSC and urological malignancies, while for some virus-
related cancers such as non-Hodgkin lymphoma (NHL ) or Kaposi sarcoma (KS) the risk was 
up to 100-fold higher.  
 
NMSCs are the most common cancers in renal transplant recipients. In contrast to the general 
population, there is a reverse relationship between the risk of basal cell and squamous cell 
carcinomas. The squamous cell/basal cell carcinoma ratio is approximately 5:1 as opposed to 
Figure. Cumulative incidence of 
malignancy in an Italian population of 
kidney transplant recipients, excluding 
non-melanoma skin cancers. 
The bold line represents all solid and 
hematologic malignancies, the dotted line 
all solid tumors, and the dashed line 
hematologic malignancies (post-transplant 
lymphoprolipherative disorders) 
Figure. Age specific 
incidence of malignancies 
in the general population 




1:4 in the general population. Squamous cell carcinoma occurs at least 25 times more 
frequently in the transplant population than the general population. In Australia, the incidence 
of skin cancer is highest in the world. Long-term immunosuppression and overexposure to 
ultraviolet light are the major causes of this increase in risk. There is also a cumulative dose-
response relationship between duration of immunosuppressive agents used and incidence of 
NMSC. The incidence of melanomas is also increased, but to a lesser extent, in renal transplant 
recipients, with an excess risk of approximately 4 times than the general population. 
For non-cutaneous malignancies (NCM), the risk is greatest among viral-related neoplasms: 
cancers related to infections, such as human herpesviruses 8 (HHV 8), Epstein-Barr virus 
(EBV), hepatitis B and C viruses, and HPV infection have been found to occur at a markedly 
increased rate, whereas non–viral-related solid organ tumors such as breast and prostate 






For instance, more than 90% of cases of posttransplant lymphoproliferative disease (PTLD) are 
of B-cell origin and associated with latent EBV infection. The overall risk, dependent upon the 
age of recipients, dose, and type of IS, increases by 3- to 10 –fold when compared with the 
age- and sex-matched general population. Recipients of older ages (> 65 years), with exposure 
to CNIs are at augmented risk. Evidence from the USRDS had demonstrated that risk for 
PTLD was highest for persons in the first post-KTx year and decreases thereafter. In Australia 
and New Zealand, and in Denmark, there was a bimodal distribution of the timing of the 
occurrence of PTLD, with an early peak within 1-2 years and with a second peak after 5 to 10 
years from transplantation. 
HPV infections, transmitted commonly through hetero- and homosexual contacts, are 
associated with various types of cancers such as NMSC, anogenital, and oropharyngeal 
cancers. The four major oncogenic strains, HPV 6, 11, 16, and 18, account for more than 70% 
of HPV-related ano-genital malignancies. Human papillomavirus infections usually remain 
dormant in sub-clinical states by an intact immune system, but could potentially be reactivated 
by IS. A higher prevalence of anogenital and cutaneous HPV infection s was observed among 
renal transplant recipients, suggesting a potential role of HPV infections in the etiology of 
these cancers.  
Moreover, a marked increase in the incidence of bladder and renal cell carcinomas by 3- and 8-
fold was observed in the renal transplant recipients when compared with the age-and sex-





For KTRs, two important exposures that contribute to increased cancer risk are unavoidable: 
end-stage kidney disease (ESRD) itself is associated with increased cancer risk at many sites 
and after transplantation, and the additional burden of the immunosuppression necessary for 
continued graft function amplifies cancer risk further. 
General lifestyle choice policies recommended for the general population such as healthy 
eating and stop-smoking campaigns have benefits in beyond cancer prevention, and it is 
generally agreed and should be encouraged and implemented in the transplant population. 
Modifiable life style risk factors known to impact on cancer risk in the general population are 
also important in transplant recipients.  
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The association between nonmelanocytic skin cancers (NMSC) and melanoma with ultraviolet 
radiation (UV) is well established. Compared with the general population, in KTRs NMSC 
develops at a younger age, and occurs more frequently at multiple sites. NMSCs also behave 
more aggressively, with more frequent recurrence after resection and metastasis, and can cause 
death, an event otherwise extremely rare.  
The pathogenic role of infections in carcinogenesis may offer opportunity to intervene to 
reduce risk. Although immunization against infections known to have oncogenic potential may 
seem an obvious preventive strategy for transplant recipients, achieving a protective immune 
response following vaccination is not always possible. People on dialysis have a reduced 
response to vaccination, with a lower antibody titer and an inability to maintain adequate 
antibody titers over time. Antibody response after transplantation is usually even worse, 
particularly in the first posttransplant year, when the burden of iatrogenic immunosuppression 
is most intense. 
Vaccination against Hepatitis B is currently recommended before the commencement of renal 
replacement therapy, along with Varicella zoster and Hepatitis A, to maximize overall response 
and seroconversion. Although primarily directed to prevent blood-borne infection and sub-
sequent liver disease in people with ESRD, Hepatitis B vaccination has a role in reducing risk 
of hepatocellular carcinoma, as people with chronic infection with hepatitis B experience a 
greatly increased risk. 
Emerging preventive measures of specific relevance to KTRs include human papillomavirus 
(HPV) vaccine against HPV-related cancers. HPV has been implicated in cancers of the 
anogenital tract (particularly cervical cancer in females) and the oropharynx and HPV DNA 
can be detected in up to 90% of skin cancers in transplant recipients (though a causative role of 





As compared to the ‘70s and ’80, graft survival has dramatically improved: the median half-life 
was 7.9 years in that era, while it is as high as 13.8 years nowadays. However this 
improvement is mainly due to a better 1-year survival and to a lower incidence of early T-cell 
mediate acute rejection after the introduction of CNIs (first cyclosporine use in 1978). Acute 
rejection rates dropped from about 50% at the time of azathioprine-steroid based-IS to less than 
10% with the use of induction sera and FK-mycophenolate based-IS.  
However, despite considerable progress, long-term graft loss in renal transplant recipients 
remains substantial, with resulting high morbidity, mortality and costs. Indeed in most Centers 
the 1-year graft survival is as high as 95%, while the 10-years graft survival is between 50% 
and 65%. In addition, patients who require re-transplantation are quite likely to be sensitized to 
HLA antigens, which significantly hinders their chances for subsequent transplantation unless 
they are desensitized. Currently, more than 5,000 kidney transplants fail each year in the US. 
The costs associated with failed transplants with return to dialysis represent a considerable 
financial burden for health care systems (MoH) while decreasing the quality and length of life 
Figure 4 Graft survival over time: on the left 1-year graft survival between 1988 and 1996, which showed 
a dramatic improvement (from 76% to 88%); on the right, survival function after the first year: no 
significant difference can be noted. 
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for affected patients. Clearly, the identification of critical pathologic pathways responsible for 
allograft loss, with the attendant development of therapeutic interventions to improve the 
duration and quality of allograft function, is one of the most important objectives of transplant 
medicine.  
Over the past two decades, our thinking has changed from considering rejection as a primarily 
T-cell-mediated process (one that is now increasingly better managed), to the realization that 
insufficient control of the humoral arm of a recipient’s immune system by current IS regimens 
is now the pathogenic factor primarily responsible for allograft dysfunction and loss. This 
notion is now progressively superseding the historical dogma that such allograft losses were 
caused by calcineurin inhibitor (CNI) toxicity and chronic allograft nephropathy (CAN). 
The most important advances in the past decade have been the implementation of sensitive 
assays for the identification of anti-HLA antibodies, improved comprehension of the pathology 
of antibody mediated rejection (AbMR) and the growing implementation of molecular 
approaches. Together, these advances have increased our understanding of antibody-mediated 
graft deterioration. Although no relevant animal model for ABMR is available, assessment of 
ABMR in humans has made major contributions to our understanding of this entity. 
 
Monitoring parameters and Pharmacogenetics of Immunosuppressive drugs 
The immunosuppressive therapy used in kidney transplantation is usually composed by a 
calcineurin inhibitor (CNI, ie: cyclosporine or tacrolimus) alone or in combination with either a 
purine-metabolism inhibitor (ie: azathioprine or mycophenolate) or a proliferation signal 





Table 2. Common IS drugs and their associations. 























Tacrolimus is the most commonly used IS drug in KTx for the prevention of allograft rejection. 
It is a lipophilic drug with high metabolic clearance and is almost completely metabolized in 
the liver and, to a lesser extent , in intestinal mucosa, via cytochrome P4503A (CYP3A) 
isoenzymes CYP3A4 and CYP3A5. Tacrolimus is also a substrate for P-glycoprotein (P-gp), a 
transmembrane efflux pump expressed in intestinal epithelial cells and biliary canalicular cells 
which affects drug absorption and excretion.  
Eight oxidized tacrolimus metabolites have been identified: one monohydroxylated (M-IV), 
three mono-demethylated (M-I, M-II, M-III), and three di-demethylated (M-V, M-VI, M-VII) 
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metabolites, in addition to a complex metabolite (31-O-demethyltacrolimus or M-VIII ). While 
M-II is equipotent to tacrolimus in terms of immunosuppressive activity, all other metabolites 
have a very weak effect. Enzyme immunoassay (EIA) techniques employ a monoclonal 
antibody against tacrolimus that also cross-reacts with its eight metabolites; however, although 
the strength of the reactivity is similar between M-II, M-III, and M-V, the remaining 
metabolites show almost negligible reactivity. 
Tacrolimus has a narrow therapeutic index and large inter-individual variations in 
pharmacokinetics, which may partly be the consequence of metabolism by CYP3A5 and P-gp. 
The expression of both proteins is affected by genetic polymorphisms: for example, patients 
with one or two wild-type allele CYP3A5*1 express CYP3A5, whereas homozygotes for 
mutant allele CYP3A5*3 are considered to be non-expressors. Consequently, variability in 
tacrolimus pharmacokinetics depends not only on interactions with concomitant drugs acting 
on CYP3A (such as ketoconazole or rifampicin), but also on a complex genetic conditioning. 
Indeed, polymorphisms of CYP3A5 would have a significant impact on tacrolimus metabolism 
while the role of MDR1 variants is more controversial. 
However, until genotypic profile data become available in daily clinical practice, tools to 
define the drug exposure profile other than the conventional and laborious dose-interval area 
under the concentration curve (AUC) would be very useful. 
Tacrolimus requirement may be easily normalized by drug levels and expressed as the 
concentration/dose (C/D) ratio , a surrogate index of tacrolimus bioavailability and 
pharmacokinetics that tends to change over the first months after transplantation and then 
stabilize after 6 months. This calculation identifies different phenotypic profiles, ranging from 
very fast to very slow tacrolimus metabolizers. Therefore, for any targeted trough 
concentration, fast and slow metabolizers need completely a different tacrolimus daily weight-
adjusted dose, leading to a low and high tacrolimus C/D ratio, respectively. 
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A relationship between the C/D ratio and the CYP3A5*1 polymorphism has been shown, as 
homozygous *3/*3 and *1/*1 patients have been shown to have the highest and lowest C/D 
ratio, respectively, and the *3/*3 genotype has been determined to represent an increased risk 
of nephrotoxicity. 
Steroids are often administered after renal transplantation, and they share some common 
metabolic and transporter pathways, such as the cytochrome P450 and P-gp systems. 
Furthermore, corticosteroids may have an induction effect on CYP3A4 expression and reduce 
tacrolimus concentration by increasing tacrolimus clearance. 
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Proposed project and specific aims 
This pilot project aims to translate the recently acquired knowledge on genes and viral-induced 
oncogenesis in the current transplantation practice. As in the past decade many studies have 
been performed on different KTx complications, I will focus on the most common ones, being 
diabetes, cardiovascular events and malignancies. Indeed, before starting intervention or 
prevention studies on such complications, an in-depth risk stratification analysis is mandatory 
and this thesis project is aimed mainly to develop risk stratification models for each transplant 
complication. The main study cohort is composed by patients transplanted at the Novara 
Transplant Center (1040 KTx performed in the past 16 years). 
The SNPs were selected from literature and previous works of our group: we focused for this 
project on four SNPs affecting tacrolimus metabolism and the rs7903146 SNP (TCF7L2 gene), 
which is the strongest associated SNP with type 2 diabetes in the general population, but may 
also interact with T-cell response. Viral detection and evaluation of replication was performed 
on small-DNA potentially oncogenic viruses, being human papilloma and polyoma viruses. 
Herpesviridae (EBV in particular) are already monitored in common clinical practice and their 
replication/reactivation was evaluated as a predictor of transplant complications. 
The main projects I’ve been working on and their study rationale are here reported in detail. 
Risk model for post-transplant diabetes mellitus 
Specific Aim: to develop a post-transplant diabetes risk model based on pre-transplant 
variables, including genetic variants which might be associated with PTDM. 
We analyzed the association of post-transplant diabetes (PTDM) with five previously selected 
SNPs in our cohort of KTx recipients (KTR). This study was also replicated for significant 
SNPs on a cohort from the Verona Transplant Center, which was indeed much different from 
ours, particularly for a shorter follow up time and a lower PTDM incidence rate. 
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Genome-wide association studies (GWAS) allowed detection of more than 100 polymorphic 
loci, which appear to modulate the risk of type 2 diabetes (T2DM) in the general population. 
While most of them appear to exert a small effect size (with OR between 1.10 and 1.20) and 
were identified in single ethnicities, a stronger effect was noted for variant rs7903146 (T allele) 
of TCF7L2 gene. The TCF4 protein belongs to a T-cell transcription factor family which 
regulates cell proliferation and differentiation through Wnt signaling pathway, which controls 
pancreas development and maturation, and islet function. T allele has been associated with 
increased protein expression, impaired insulin secretion, impaired incretin effects and hepatic 
insulin resistance. As beta-cell dysfunction –rather than insulin resistance– is possibly a 
predominant pathophysiological mechanism for PTDM, some studies confirmed the role of 
TCF7L2 rs7903146 C>T also in this setting. However other investigations, did not detect this 
association, making results inconclusive. Therefore, although association of this TCF7L2 
polymorphism with PTDM remains highly plausible from a biological point of view, its 
clinical role remains to unclear and it is not routinely genotyped to predict individual risk of 
PTDM before KTx. 
As only the TCF7L2 polymorphism was associated with PTDM among studied SNPs, we 
performed a meta-analysis combining the present results with data of previously published 
studies to clarify the relationship between rs7903146 and the risk of PTDM in renal transplant 
patients. As the meta-analysis found a significant association between PTDM and rs7903146 
TT genotype, we built a predictive model of PTDM including this polymorphism and 
environmental parameters. 
This analysis gives a powerful predictive model of PTDM based on pre-transplant variables, 
which may be helpful in the clinical management of KTRs, also in the first days after surgery, 
a time period in which glucose-toxicity may be very relevant. Moreover as TCF7L2 rs7903146 
T allele is associated with beta cell dysfunction, novel preventive strategies will be tested in 




Specific Aims: to evaluate the impact of different therapies (treated as “environmental” risk 
factors) on post-transplant thrombotic events (both early and late events). 
To evaluate if SNPs associated with IS metabolism or complications may indeed alter the risk 
of thrombotic or cardiovascular events. 
To develop a risk model for specific post-transplant CVE based on pre-transplant variables. 
As detailed above, cardiovascular events (CVE) have a complex pathogenesis in KTRs. We 
first evaluated those “environmental” factors which can be modified, particularly 
immunosuppressive therapy and pharmacological prevention strategies, focusing on 
thrombosis and thrombotic events.  
The management of antiaggregant therapy both in elective –such as living donor KTx- and in 
urgent surgery –as deceased donor KTx- is an evolving issue: international consensus and 
guidelines suggest to evaluate bleeding and thrombotic risk for decision making, but no 
specific recommendation is made for kidney transplant surgery. Actually KTR represent a very 
peculiar population in which baseline thrombotic and hemorrhagic risk are both elevated if 
compared with the general population, as ESRD is associated with complex and severe 
vascular alterations and sub-clinical inflammation and, on the other side, platelet aggregation 
defects. Therefore results inferred from different populations might not directly apply to KTx 
surgery or recipients. 
On these basis, we performed a retrospective analysis on 911 consecutive KTx to analyze the 
impact of antiplatelet or oral anticoagulation therapy on thrombotic events, which might be 
related to their withdrawal after surgery, and to identify the main risk factors for early (within 
90 days from surgery) events. Moreover, even if initial IS was not associated with CVE, I 
investigated the role of mTOR-inhibitors (mTORi), which are a relatively common 
maintenance IS therapy.  
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Moreover, as different IS medications have been involved in the pathogenesis of thrombotic 
events. Recently, Baas et al have shown that KTR receiving everolimus have higher levels of 
inhibitors of fibrinolysis, which may be associated with more thrombotic events. Indeed, some 
case reports described devastating thrombotic events in solid organ transplant recipients treated 
with mTORi, but randomized controlled trials did not describe an increased risk of vascular 
complications. Therefore we retrospectively studied the incidence of major thrombotic events 
(MTE) in a cohort of unselected KTRs to evaluate if patients experienced more MTE while on 
mTORi. 
Lastly we investigated the association of the above studied SNPs with CVE and cardiac 
ischemic events (symptomatic ischemic heart disease and acute myocardial infarction (AMI) in 
particular, including non-diabetic KTRs followed-up at our Center. Indeed, only TCF7L2 
rs7903146 showed a significant association with cardiac ischemic events and a risk-prediction 
model was developed. The role of rs7903146 T allele in modulating cardiovascular risk in the 
setting of KTx is biologically plausible and could be mediated by a wide range of mechanisms. 
TCF-4 transcription factor is involved in the pathway of NF-kB: a dysregulation of this axis 
can alter bone remodeling, a key process leading to coronary artery calcification (CAC), and 
promote vascular wall inflammation, oxidation and endothelial dysfunction. Interestingly, we 
found a stronger association of the allele with CAD in KTRs than in the general population, as 
we showed also for PTDM. This increased strength of association could be explained by the 
fact that genetic predisposition can emerge more clearly in KTx setting due to a higher event 
rate caused by interaction of polymorphisms with transplant-specific environmental factors 
such as IS therapy and chronic renal failure.  
Indeed, we could come up with a predictive model of acute thrombosis in the first post-
transplant months, an integrated gene-clinical model for the prediction of ischemic heart 
disease and define the risk of thrombosis associated with a specific class of IS, which is used 




Genetics or viruses determine viral-related malignancies? 
Specific Aims: to evaluate the role of active HPV on NMSC development in KTRs. 
To evaluate the role of active HPyV or BKV-associated nephropathy on the development of 
tumors of the urinary tract in KTRs. 
To evaluate if SNPs associated with IS metabolism or complications may indeed alter the risk 
of virus-related malignancies. 
To identify risk factors and clinical biomarkers of PTLDs. 
We investigated post-transplant malignancies from both susceptibility genes and viral 
determinants, including five pre-determined SNPs, clinical pharmacokinetic parameters, and 
viral replication indexes, focusing on viral-associated malignancies, particularly on NMSC, 
PTLD and urinary tract tumors. 
Most of the cancers with an elevated standard incidence rate (SIR) are caused by reactivated 
viruses whose oncogenic potential is suppressed by immunological reactions in healthy 
individuals. A role for beta HPV in the development of NMSC has been repeatedly reported by 
a series of epidemiological, seroepidemiological and experimental data. A similar scenario can 
be envisaged for human polyoma virus (HPyV) whose causal association with human tumors is 
also difficult to be established because they may also be constituents of the human skin and 
urinary tract microbiome. 
HPVs and HPyVs share a common morphology and structural organization, being small, 
circular DNA viruses. Cutaneous beta-HPVs cause widespread unapparent or asymptomatic 
infections in the general population: however, in immunosuppressed patients these viruses can 
spread unchecked and have been implicated in the development of skin cancer.  
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The aim of this retrospective study was to determine the incidence of virus-related cancer in a 
cohort of kidney transplant recipients, focusing on their association with HPV or HPyV 
reactivation. 
Moreover previously studied SNPs affecting CNI metabolism were studied as potential risk 
factors for virus-induced cancer development, particularly PTLD: their interaction with EBV 
status and reactivation has been analysed in our large cohort. Lastly a large case-cohort study, 
involving nine transplant centers, on PTLDs was performed to identify risk factors for this rare, 
but severe complication, including EBV status, immunosuppressive therapy and 
pharmacokinetic parameters. As this study collected data retrospectively and most patients 






Patients and Methods 
Data collection and cohort definitions 
Novara “full” cohort 
We conducted a retrospective analysis of all adult KTx performed in a single Kidney 
Transplant Centre from its opening in November 1998 up to December 2014, including 
deceased donor (94.6%) and living donor (5.4%) KTx. As the database is constantly updated 
and analysis were performed at different times, this same population in different analysis might 
vary. Moreover inclusion criteria may change depending on the specific aim which is 
investigated, as shown in Table 1. 
 
Table 1. Analyses performed on the entire Novara cohort, reporting year, population 
selection criteria and numerosity of included population 





Early post-KTx thrombotic 
events 
2014 All patients None 911 
mTORi effect on 
thrombosis 
2013 All patients with 
complete IS data 
None 694 
Malignancy incidence 2015 All patients None 1040 
 
Pre-transplant work up included medical history, echocardiography and Doppler-ultrasound 
evaluation of peripheral arteries and veins; if a patient was older than 50, or diabetic, or had 
had a previous cardiac event, a stress test (usually a nuclear medicine perfusion scan or a 
dobutamine stress echo) was performed and the patient was treated accordingly. Patients with 
previous multiple TE, including miscarriages, deep venous thrombosis, pulmonary embolism 
or vascular access thrombosis, were evaluated for genetic and acquired causes of 
thromobophilia and treated accordingly. 
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Moreover, a strict pre-transplant screening for malignancy and pre-malignant lesions is 
performed at our Center in order to exclude from transplantation patients with an active 
neoplasia, including dermatology evaluation, chest x-ray, abdomen CT, gastroscopy, thyroid 
US, protein electrophoresis, and specific sex- and age-related screenings like colonoscopy 
(patients older than 50), PSA and urological evaluation, mammogram and PAP test. Moreover 
each patient with a particular risk factor or pre-malignant lesion (for example an MGUS) is 
evaluated with specific exams and visits. Patient with a previous malignancy but considered 
free from disease are re-evaluated at the Transplant Center and depending on the tumor 
histology and stage may be admitted to the KTx wait list after 2 to 5 years from the end of 
therapies. 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Dual 0 0 0 0 0 0 3 6 3 6 6 9 8 2 2 5 4
Single 5 41 44 62 56 60 63 71 74 62 54 56 67 61 51 63 48
Living 0 0 0 0 0 1 2 3 5 2 7 4 4 7 4 5 13
n
year
Transplant in Novara by year year
Living Single Dual




Table 2. Baseline characteristics of the latest cohort analysis (1040 
transplants in 1028 recipients). Variables are expressed as mean ± St dev 
or %. 
Age at KTx 51.3 ± 12.5 
Sex (Male) 661/1040 (63.6) 
Ethnicity (Caucasian) 1005/1040 (97.1) 







  90/1040 (8.7) 
    9/1040 (0.9) 
Living Donor 60/1040 (5.8) 
HCV (Positive) 86/1040 (8.3) 
Pre-Transplant Diabetes 65/1040 (6.3) 
Body Mass Index 24.0 ± 3.5 
Peak Reactive Antibodies > 0% 294/1040 (29.3) 


















  93/1040 (8.9) 
934/1040 (89.8) 
  15/1040 (1.4) 
  46/1040 (4.4) 
  35/1040 (3.4) 
Delayed graft function 234/1025 (22.8) 
One or more acute rejection episodes 91/1040 (8.8) 
Creatinine at hospital discharge (mg/dL) 2.05 ± 0.85 




Novara “gene” cohort 
We proposed this study to all patients transplanted in our Kidney Transplant Centre, of which 
542 accepted to be included in the study. Patients were proposed to be included in the study at 
the time of KTx from 2009 to 2014 or at a follow up visit if they were transplanted earlier (the 
older transplants dating back to year 2000). No particular exclusion criteria was chosen for 
patient enrolment. However specific analyses were limited to each study’s interest population. 
Enrolled patients underwent genetic analysis of five SNPs of four genes, as detailed below. 
Their main clinical characteristics (Table 3) are similar to those of the population from which 
they have been enrolled (Table 2). However as some patients have been enrolled during a 
follow up visit a selection bias (ie: patients alive with a functioning graft are more likely to be 
included) cannot be excluded. 
Table 3. Clinical characteristics of the patients enrolled in the genetic 
studies (Novara-gene cohort) 
Age (years) 52.4 ± 12.2 
Male 64.4% 
Ethnicity (Caucasian) 98.4% 
Years on dialysis 4.00 ± 3.68 
Previous transplants 9.1% 
Living Donor 4.7% 
Pre-transplant Diabetes 6.6% 
BMI (Kg/m2)  24.1 ± 3.46 
Peak PRA > 20% 8.3% 
Total HLA mismatches  2.87 ± 1.04 
Induction therapy: 
 None 
















Delayed Graft Function 21.9% 
One or more acute rejection episodes 10.2% 
Serum Creatinine at discharge (mg/dL) 2.06 ± 0.94 





Verona “gene” cohort 
As confirmatory cohort for genetic study, we asked for a collaboration to the Transplant Center 
of Verona: this cohort includes kidney transplant recipients transplanted in Verona and who 
accepted to undergo genetic analyses (n=190). However this cohorts includes five kidney 
transplants in patients with already another transplanted organ (lung or heart). All of these 
patients were enrolled at a follow up visit in 2012-2013, which was from one to twenty years 
after transplantation: therefore this population is heterogeneous and selected as only patients 
alive and with a functioning graft in 2012 were proposed to enter the study. 
Moreover the baseline characteristics of this cohort are quite different from the patients from 
the Novara-gene cohort (Table 4). Particularly this cohort has more KTx from living donors, 
less previous transplants, less immunized patients (defined as PRA > 0%) and their 
immunosuppression has much less use of tacrolimus in favour of cyclosporine. 
Table 4. Clinical characteristics of the Verona cohort (n=190) 
Age (years) 50.0 ± 13.4 
Male 64.4% 
Ethnicity (Caucasian) 96.3% 
Previous transplants 5.3% 
Living Donor 11.7% 
Pre-transplant Diabetes 5.8% 
BMI (Kg/m2)  24.5 ± 4.16 
Peak PRA > 0% 4.0% 
Total HLA mismatches  3.53 ± 1.30 
Induction therapy: 
 None 
















One or more acute rejection episodes 5.7% 
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Moreover follow up data are lacking in some patients, particularly for older transplants. Indeed 
the more severe complications (leading to patient death or graft failure) were not reported as 
this cohort was enrolled cross-sectionally. 
 
Parma case-cohort study 
I’ve participated in a multicenter study coordinated by the Parma Transplant Center, started in 
2010. Their main aim was to determine whether a post-transplant lymphoproliferative disorder 
(PTLD) affects death-censored graft survival. PTLD was defined as any lymphocyte malignant 
proliferative disease, including both lymphomas and leukemias. Involved transplant centers 
were Parma, Novara, Milano Policlinico, Pavia, Cagliari, L’Aquila, Catania and Matera. 
However, as they enrolled a large case-cohort population, we investigated together the risk 
factors for this rare complication (<1% of KTRs). They had no DNA for any patient, so this 
confirmatory cohort was used to determine which clinical and therapy variable are associated 
with an increased risk of PTLD: indeed, four of the SNPs we studied affect CNI metabolism 
and their effect might be estimated from phenotypes of KTRs. 
We have enrolled 49 cases of PTLD, most of which (n=24) were diagnosed among KTRs 
referring to Parma. Each case was matched to four control KTR at the time of transplantation 
(case-cohort study) by age (± 5 years), sex, transplant center, year of transplantation (±2 years) 
and transplanted organ (living vs. deceased donor). Only patients at their first kidney transplant 






D: disease appearance (PTLD), cases; Arrow: lost to follow up 
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Data from cases included all relevant clinical and demographical characteristics. For all 
patients we included baseline characteristics and follow up data on anthropometric measures, 
renal function, rejections and IS therapy. The main clinical characteristics of cases and controls 
are reported in Table 5. 
Table 5. Baseline characteristics of Cases and Controls of the Parma 







Female 24,5% 25,0% 0,941 
Age 42.0 ± 14.6 42.6 ± 13.6 0,814 
Months on Dialysis 36.0 ± 32.7 49.9 ± 51.2 0,164 
Mismatch HLA 3.12 ± 1.27 3.07 ± 1.18 0,808 




Ab anti IL2R 63,3% 65,1% 
No induction 51,0% 47,6% 
Tacrolimus 38,7% 31,6% 0,253 
MMF 40,8% 40,3% 0,792 




Clinical variable definitions and management 
Main clinical and demographical variables were collected in an “ad hoc” database of the 
Novara cohort, focusing on pre-KTx history and therapy, cardiovascular risk factors and 
transplant-related variables. This database can he easy linked with the kidney donors’ database 
managed in Torino (Immunologia dei Trapianti Regionale – ITR) and with the genetics 
database (Dipartimento Scienze del Farmaco – DSF) through a unique coding system. 
Data management was performed by the Epidemiology Unit of our hospital. Internal and 
validation checks of the entered data were performed periodically twice a year. 
The DB has a multilevel structure as represented in Figure. 
 
Data of the Verona cohort were extracted from the local database of kidney transplants. 
Data of the Parma case-cohort study were already recorded in two worksheets, the first 

























point). Data were collected from local patient records and entered in the central database by a 
local investigator and reviewed by two investigators from the coordinating Center. 
The variable and event definitions are widely accepted and indeed all three databases used the 
same definition criteria for corresponding variables. 
 
Events: 
 Death is recorded from referring nephrology centers. The cause of death is determined 
through autopsy when available or by the caring physician otherwise. The initial main 
cause of death is reported in the database and grouped in cardiovascular death, malignancy, 
infection or other. 
 Graft failure is defined as the need of any chronic renal replacement therapy after the KTx. 
Chronic rejection was diagnosed with renal biopsy performed for a worsening renal 
function or clinically by the presence of a progressive renal function deterioration, 
increased urinary proteins and presence of donor-specific antibodies (DSA), after excluding 
other plausible causes of renal damage. No patient developed a graft failure due to a late-
onset acute rejection. Graft failure due to other causes was usually diagnosed by renal 
biopsy and included relapse of underlying nephropathy, new onset (“de novo”) 
nephropathies (including paraneoplastic nephropathies, like myeloma kidney), BK virus 
associated nephropathy, chronic vascular nephropathy (including cardio-renal syndrome), 
chronic pyelonephritis, and chronic obstructive/reflux nephropathy: these cases have been 
included in the group of “graft failure not due to chronic rejection”. 
 Primary non function is defined as the need of chronic dialysis within 3 days from surgery 
in the absence of any sign of graft function (ie: creatinine never going down after surgery). 
 Diabetes was defined according to the 2013 American Diabetes Association Guidelines as a 
glycated hemoglobin (HbA1c) ≥ 6.5%, or a fasting plasma glucose ≥ 7.0 mmol/L (126 
mg/dL), or a 2-h plasma glucose ≥ 11.1 mmol/L (200 mg/dL) during an oral glucose 
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tolerance test in two 30-days apart samples or a fasting plasma glucose of at least 11.1 
mmol/L (200 mg/dL) with symptoms of hyperglycemia or use of any hypoglycemic agent 
for at least 30 days. This definition has been employed to define diabetes before KTx and 
after KTx; particularly the “therapy criteria” is important in the early post-transplant days, 
as sometimes patients need insulin for a few days (less than 30) during the high-dose pulse 
steroid therapy that is commonly used in the first days after surgery. Moreover a diagnosis 
of PTDM was made only once the transplant was stable and first evidence of 
hyperglycemia was employed as “event date”. As we performed a diabetes-free survival 
analysis we did not include a post-transplant time cut-off to define post-transplant diabetes 
(PTDM), as recent literature suggests not to include a time-frame in the definition of 
PTDM. 
 Thrombosis definition included death for cardiovascular causes, allograft loss for 
thrombosis, renal artery or vein thrombosis, AMI, stroke, transient ischemic attack and 
deep vein thrombosis with or without pulmonary embolism . 
 Cardiac ischemic events included symptomatic ischemic heart disease and myocardial 
infarction. Symptomatic coronary artery disease (CAD) was defined as needing or 
prolonging an hospital admission for angina pectoris, including the ICD-9 diagnosis codes 
411.1, 413, 413.0, 413.1 and 413.9. Acute myocardial infarction (AMI) was defined as 
needing or prolonging an hospital admission for an acute coronary syndrome, including the 
ICD-9 diagnosis codes from 410 to 410.9. All events required specific therapy, including 
medical therapy, percutaneous or surgical revascularization, or a combination of them.  
 Malignancy was diagnosed histologically or –rarely- on clinical bases, the latter case being 
relevant only for NMSC, which were sometimes treated with cryotherapy. All KTRs 
referring to our Center are proposed to cancer screening as for the general population 
(breast, prostate, colon-rectum, cervix-uterus), and additionally they undergo to a yearly 
dermatologic evaluation, abdomen ultrasonography, and chest X-ray. NMSC included skin 
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lesions with the ICD-9 code 173, being basal cell carcinomas and squamous cell 
carcinomas; no Merkel cell carcinomas were diagnosed. NCM included all other invasive 
malignancies, including both solid and hematologic tumors and excluding pre-cancerous 
lesions: the ICD-9 codes included 140 to 172 and 174 to 208. 
 PTLD was defined as any malignant lymphocyte proliferation after KTx, including 
lymphomas and leukemias. In the Parma case-cohort study we observed the following 
diseases: early lesion (high grade EBV-related oligoclonal dysplasia), polymorphic 
lymphoma (oligoclonal lymphoma with various differentiations), large-B-cell diffuse 
lymphoma, monomorphic T cell lymphoma, other monomorphic B-cell lymphoma, 
Hodgkin disease, large granular lymphocyte leukemia, chronic lymphocytic leukemia. 
 
Other variables 
 Delayed graft function is defined as the need for dialysis in the first week after 
transplantation, regardless of the indication, including dialysis for isolated hyperkaliemia. 
No creatinine criteria is included in this definition, even if in the changing transplant 
population it has been advocated by some authors. This definition is highly specific for 
DGF and DGF defined according to this criterion has been shown to predict accurately long 
term graft failure. The inclusion of a creatinine criterion improves the sensitivity of DGF, 
but reduces its specificity. Moreover if a patient is transplanted pre-emptively (ie: before 
starting dialysis) it is very unlike to start dialysis after transplantation. Lastly, patients with 
a follow up shorter than one week (death or primary non function) have this variable left as 
missing. 
 Acute rejection is usually defined histologically according to the Banff classification and 
subsequent revisions, including the 2013 revision which re-defines acute and chronic 
antibody mediated rejection. Sometimes -when a kidney biopsy is contraindicated or 
considered to be too risky- it was defined clinically as a rise in serum creatinine more than 
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2 times the baseline level or a persistent creatinine of more than 6 mg/dL in the presence of 
active urinary sediment (hematuria or proteinuria) and that recovered within one week of 
high-dose steroid pulses (more than 1000 mg cumulative iv dose). 
 Chronic rejection was diagnosed with renal biopsy performed for a worsening renal 
function as defined by the Banff 2013 criteria or clinically by the presence of a progressive 
renal function deterioration (eGFR slope lower than -5 ml/min/1.73m2/year), increased 
urinary proteins (>0.5 g/24h) and presence of donor-specific antibodies (MFI > 3000), after 
excluding other plausible causes of renal damage 
 Parthormone has been divided in tertiles for analyses. This decision was taken as PTH in 
the general CKD population shows a U-shaped curve when related to cardiovascular risk. 
 BKV nephropathy: diagnosed histologically by specific BKV-related cytopathic inclusions 
and changes and a positive SV40 staining. It has been rarely diagnosed clinically as BKV 
viremia greater than 10.000 copies/mL with a worsening renal function or with an 
increasing tubular proteinuria greater than 0,5 gr/24h 
 Pharmacokinetic profile 
o Weight normalized daily dose: daily drug dose in mg (usually CyA or Tac) divided by 
patient’s weight in kilograms. A high value means that the patient assumes a high 
dose of the IS drug. 
o Dose normalized through level: through level in ng/mL (usually measured for CyA or 
Tac) divided by the weight normalized daily dose. A high value means that the patient 
reaches a high through level given a fixed weight-adjusted IS drug dose, ie: he has a 
slower metabolism/higher absorption and might be more exposed to IS drugs. 
o Coeficient of variability: it can be calculated if a patient has at least three consecutive 
IS drug trough level. It is calculated as the ratio between the standard deviation of 
through levels and their mean value. It is usually expressed as a percentage. It has 
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been associated with a higher risk of graft failure probably because it might be sign of 
poor therapy compliance. 
 Antiaggregant and anticoagulant management strategies. Patients on VKA underwent 
transplantation only after the PT-INR was lower than 1.7, which was achieved through 
transfusion of fresh frozen plasma and/or vitamin K. After surgery, if the indication to 
anticoagulation persisted (ie: it was not for vascular access patency) and there was no 
clinical or ultrasound evidence of active bleeding, they started enoxaparin within 12-24 
hours from KTx, at a dose able to reach an anti-factor Xa activity target of 0.5 – 0.9 IU/mL. 
Patients on AAT stopped drug administration on the day of surgery, and they resumed it 
after one or two months, if still indicated. Meanwhile a bridge therapy with enoxaparin was 
given to reach an anti-factor Xa activity of 0.3 – 0.5 IU/mL. All the other patients received 
a deep venous thrombosis prophylaxis with anti-embolism compression stockings or 
enoxaparin (anti-factor Xa activity target of 0.3 – 0.5 IU/mL) up to two weeks after 
surgery. Anti-Xa activity measurement was available in our Center since 2004 and 
previously it was used at a dosage of 2000-4000 IU qd for deep vein thrombosis 
prophylaxis while for parenteral anticoagulation (ie: prosthetic heart valve) unfractionated 
heparin or enoxaparin 4000 IU bid have been used. 
 
Laboratory methods 
SNPs genotyping: we investigated the following SNPs: CYP3A5 *1 and *3 (6986A>G), CYP3A4 
rs35599367C>T, ABCB1 (MDR1, P-glycoprotein) rs1045642 (3435C>T) and rs1128503 
(1236C>T), and TCF7L2 rs7903146C>T. 
Genomic DNA was extracted from peripheral blood by using the QiaAmp DNA Mini Kit 
(Qiagen Valencia, California, USA). Genotyping was performed by real-time PCR using 
Applied Biosystems TaqMan Pre-Designed SNP Genotyping assays. Real-time PCR 
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amplification and detection was conducted on genomic DNA in 48-well PCR plates using a 
MiniOpticon PCR Detection System (Bio-Rad, Milan, Italy), as previously reported. Reaction 
was set up in a final volume of 10 μl containing 10 ng genomic DNA, 1× TaqMan Genotyping 
Master Mix (Applied Biosystems) and 1× SNP genotyping assay. Briefly, thermal cycling was 
initiated with a denaturation step of 10 min at 95 °C, followed by 50 cycles of 15 s at 95 °C and 
90 s at 60 °C. After PCR was completed, allelic discrimination was analyzed using the Bio-Rad 
CFX Manager Software (Version 2.1, Bio-Rad). Genotype assignment was determined by 
plotting the end point relative fluorescent units (RFU) for one fluorophore (allele 1 on the x-axis) 
against the RFU for the other fluorophore (allele 2 on the y-axis) on the allelic discrimination 
plot. All reactions of real-time PCR were set up in a dedicated PCR area with dedicated PCR 
pipettes and reagents. For quality control purposes, each Real-time PCR included negative as 
well as positive controls for the three genotypes. For validation, about 15% of the samples were 
re-genotyped. The results were reproducible with no discrepancies in genotyping. Genotyping 
was performed blinded to all clinical data. 
Antibodies, protein-protein (immunofluorescence) double detection, immunohistochemistry and 
fluorescent in situ hybridization (FISH) of HPV and polyomaviruses 
Tissue sections were obtained from formalin fixed and paraffin-embedded blocks, previously 
collected and stored in the University Hospital medical material archives. 
Antibodies: the polyclonal antibodies raised against the HPV β genus E4 and L1 proteins, and 
the HPV α genus E4 protein (namely PanHPVE4). The α-genus HPV L1 antibodies were 
obtained from DAKO Corp (Carpinteria, CA), minichromosome maintenance protein 7 (MCM7) 
from Neomarkers Fremont (Fremont, CA), p16 (clone E6H4) and Large T SV40 (clone MRQ-
4) from Ventana Medical System (Tucson, AZ).  
Consecutive 5 m sections obtained from formalin-fixed paraffin-embedded tissues were 
processed for the immunofluorescent protein-protein double detection, and in 
immunohistochemistry using the automated immunostainers BenchMark ULTRA stainer 
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(Ventana Medical System, Tucson, AZ).  
Large T– positive cases were further tested by DNA-fluorescent in situ hybridization (FISH) 
using a probe derived from nick translation of the entire BKHPyV genome (Biotin Nick 
Translation Mix, Roche, Basel, CH). 
Images were acquired using a digital scanner (Pannoramic MIDI; 3D Histech Kft., Budapest, 
Hungary). For the assessment of histological features, the slides analyzed by α/β-HPVE4-MCM7 
(or BKPyV DNA) were disassembled and stained with hematoxylin and eosin (H&E). 
 
Data analysis 
A p value<0.05 was considered statistically significant for all statistical analyses. Statistical analysis 
were performed with SAS 9.2 (Statistical Analysis System) software or MedCalc Version 13.3.3 
(MedCalc Software, Mariakerke, Belgium) software. 
Post-Transplant Diabetes 
Chi square test was used to compare categorical variables; Wilcoxon Two Sample test and 
Kruskall-Wallis test were used to compare continuous variables as appropriate. ANOVA test 
was used for univariate analyses. Gene variations were tested for deviation from the Hardy-
Weinberg equilibrium by use of the Pearson's chi-square test implemented in the online Finetti’s 
program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Event-free survival analysis was performed with 
an actuarial Kaplan-Meyer method, defining the event as diagnosis of PTDM and censoring 
patients without event at the time of graft failure, death or last visit; time to event was measured 
from the day of KTx to the first diagnosis of PTDM or patient censoring. 
The analysis of the risk factors associated with PTDM was performed using a multivariate Cox 
model with the same end-point as the event-free survival analysis.  
We first used a forward stepwise inclusion method and automated selection of significant 
variables, including always age, sex and TCF7L2 genotype and, in order, body mass index (BMI) 
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at KTx, acute rejection episodes, delayed graft function, peak panel reactive antibodies (PRA), 
use of tacrolimus, ethnicity (Caucasian vs other), as well as those variables that were 
significantly associated at the univariate analysis (previous transplants and cold ischemia time 
divided in quartiles). For TCF7L2 rs7903146, we considered either an additive, a dominant or a 
recessive mode of inheritance. For model parsimony, only variables with statistically significant 
hazard ratios were considered in the construction of predictive models for PTDM. The Cox’s 
proportional hazard regression coefficients of each included parameter were converted into an 
integer risk score by rounding the quotient of dividing the regression coefficient by a single 
constant. To evaluate the predictive accuracy, the receiver operating characteristic (ROC) curve 
for each model was derived and the area under the ROC curve (AUROCs) was calculated. 
 
Meta-analysis of TCF7L2 rs7903146 and risk of PTDM in renal transplant 
patients  
We carried out a computerized literature search from Web of Knowledge and Pubmed 
databases (up to 30 June 2015) by using the Boolean combinations of the key terms: TCF7L2 
AND (allograft OR transplantation OR transplant) AND (kidney OR renal) AND diabetes. We 
searched for all articles published in English that evaluated the association between TCF7L2 
rs7903146 and risk of PTDM in renal transplant recipient. The identified articles had to meet 
the following criteria: 1) sufficient genotype data to calculate the odds ratios (ORs) with 95 % 
confidence intervals (CIs). Exclusion criteria were as follows: 1) insufficient information, for 
example, genotype frequency or number not reported; 2) studies that were not published in 
English; 3) review articles and duplication of previous publication. The retrieved studies were 
then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. If 
two or more studies shared part of the same patient population, the more complete or the one 
with the larger sample size was included. All references cited in the eligible studies were also 
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reviewed to identify additional published works that were not initially retrieved. A 
standardized form was used for each of the included studies, in which the following 
information was filled: the first author’s last name, year of publication, number of patients, age, 
gender, ethnic background, proposed genetic contrasts and time of PTDM evaluation. All 
studies were independently analyzed by two of our collaborators and any discrepancies in data 
extraction were resolved through consensus. The strength of the correlation between TCF7L2 
rs7903146 and risk of PTDM was calculated using ORs, and the precision of the estimate was 
given by 95%CIs. When any zero cell occurred in the two-by-two contingency table, we added 
a Woolf–Haldane continuity correction of 0.5 to generate a finite OR. Data were combined 
using random-effects (DerSimonian and Laird) models which incorporate the between-study 
heterogeneity and allow for a different effect in each population. In case of lack of 
heterogeneity, the random-effect model coincides with the fixed-effect model. We estimated 
the between-study heterogeneity across all eligible comparisons by using the Cochran’s Q chi-
square test (significant for P <0.10). We also reported the I2 index, which quantifies 
heterogeneity irrespective of the number of studies. Meta-analysis was performed with Open 
Meta-Analyst available at http://www.cebm.brown.edu/open_meta/ (Joseph Lau, Boston, 
Massachusetts). Publication bias was investigated using funnel plots, with a roughly 
symmetrical distribution on either side of the summary estimate suggesting a lack of bias. The 
presence of possible publication bias was evaluated graphically by drawing funnel plots for 
each outcome measure and statistically by means of Egger’s standard regression test. 
Calculations of publication bias were performed using StatsDirect statistical software version 
3.0.146 (Stats-Direct Ltd, Cheshire, UK) and p-values <0.10 were considered to indicate 






Early thrombotic events 
Only early thrombotic events were considered as outcomes, being defined as occurring within 90 days 
after transplantation.  
Chi square test was used to compare categorical variables; Wilcoxon Two Sample test and Kruskall-
Wallis test were used to compare continuous variables as appropriate. ANOVA test was used for 
univariate and multivariate analyses. As the events were recorded in the first 90 days after KTx and all 
patients had a follow up longer than 90 days, logistic regression analysis were performed. 
A multivariate logistic regression model for early CVE was developed by a step-wise forward 
procedure starting from the most strongly associated variables to assess the independent risk factors for 
CVE, taking into account at each step only the significant variables or those that significantly altered 
the estimated OR of previously included risk factors. 
 
Thrombosis and mTORi 
A total of 694 adult patients were enrolled fora total follow-up time of 3943 pt-years: patients who 
started an mTOR-I at the time of transplant (n 52) and those who were later switched to an mTOR-I (n= 
115) were compared to patients who have never been on mTOR-I (n = 527).  
The incidence rate of thrombotic events was calculated on the total time on therapy for 
immunosuppressive regimens including mTOR-I  versus all the other immunosuppressive regimens, 
dividing the number of events by the total time at risk. Comparisons between groups were performed by 
































Ischemic heart disease 
Data were summarized and presented in the form of mean, standard deviation, and percentage 
as descriptive statistics. Comparisons between genotype groups were performed by one-way 
analysis of variance (ANOVA) for continuous variables and chi-square analysis for categorical 
variables. SNPs were tested for deviation from the Hardy-Weinberg equilibrium by use of the 
Pearson's chi-square test implemented in the online Finetti’s program (http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl).  
The effect of clinical variables on the risk of post-transplant CAD was first evaluated by 
univariate analysis, using the Chi square test for categorical variables and Wilcoxon Two 
Sample test or Kruskall-Wallis test for continuous variables as appropriate. Genotype 
frequencies were compared between patients with and without post-transplant CAD using the 
Armitage trend test for additive effect of rs7903146.  
Event-free survival analysis was performed with an actuarial Kaplan-Meyer method, defining 
the event as diagnosis of CAD and censoring patients without event at the time of graft failure, 
death, diagnosis of post-transplant diabetes or last available visit; time to event was measured 
from the day of KTx to event or patient censoring.  
We developed a multivariate Cox model using a backwards stepwise method, including always 
TCF7L2 genotype and age, sex, previous ischemic cardiac events, time on dialysis, statin use 
as well as potential explanatory variables with a cutoff of P value <0.10 from univariate 
analyses (HLA mismatches and delayed graft function-DGF). Other variables that have been 
evaluated in the univariate analysis but did not result significantly associated with CAD at 
multivariate analysis were estimated glomerular filtration rate (eGFR, estimated with the CKD-
EPI formula) at hospital discharge from KTx, antiaggregant therapy prior KTx, total 
cholesterol, LDL cholesterol, previous smoking, parathormone levels, previous 
parathyroidectomy, arterial hypertension, type of dialysis (hemodialysis, peritoneal dialysis, 
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pre-emptive transplantation), peak panel reactive antibodies (PRA), use of tacrolimus, presence 
of a monoclonal gammopathy of undetermined significance, and acute rejection episodes. 
 
Malignancies: effects of viruses and genetics 
NMSC included SCC and BCC, while no Merckel cell carcinoma was observed. All other solid 
and hematologic malignancies, including “in situ” carcinomas and malignant melanoma, were 
included as NCM at the time of their first diagnosis. In the analysis of genital alpha-HPV-
related tumors we included both malignancies and precancerous lesions, such as high grade 
cervical dysplasia.  As patients might have had multiple lesions, each group of tumors was 
treated as a separate variable such that a single patient could end up in several groups. 
Descriptive statistics were performed and results presented as means ± standard deviations or 
as events/patients (%). For incidence analysis, only the first tumor in each group was 
considered. The cumulative incidences of malignancies were calculated considering death and 
graft loss as a competing event. A univariate Cox-survival analysis was used to look for 
clinical risk factors for each malignancy. 
To illustrate the effect of BKVAN occurrence over time on the risk of graft failure, we used a 
modified Kaplan-Meier method that estimated cumulative incidence of urinary tract 
malignancy according to the presence or absence of BKVAN. All patients at the beginning of 
the observations were included in the BKVAN-free group, and the assignment to the BKVAN 
group was updated at the time of the BKVAN diagnosis. To quantify the BKVAN effect in 
terms of hazard ratio, we fitted a univariable Cox model including BKVAN as a time-






PTLD: case-cohort study 
This is a retrospective case-cohort study. We defined as ‘‘index time’’ the time of PTLD 
diagnosis in the cases and the corresponding time from transplant in the controls. Because 
some controls did not reach the index time, some of them were lost before index time because 
of graft failure or death. 
Then we evaluated risk factors for PTLD with an event-free survival, considering PTLD as the 
event and censoring patients if they died, returned to dialysis or last available visit. All 
available baseline variables were tested as predictors in the PTLD-free survival analysis, first 
in univariate models, and then we developed a multivariate Cox model including significant 
variables. 
Moreover we performed a pilot analysis of post-transplant variables potentially associated with 
PTLD development, particularly IS therapy and its interaction with EBV serological status at 
baseline. As all cases reached the “index-time”, but not all controls did, we performed a 
multivariate logistic regression including patients who reached the “index time”, using PTLD 







Specific Aim: to develop a post-transplant diabetes risk model based on pre-transplant 
variables, including genetic variants which might be associated with PTDM. 
Population and risk factors for PTDM 
We included 464 patients (52.4 ± 12.3 years, 65.3% males): they were mainly Caucasian 
(97.4%), received a KTx from a deceased donor (95.7%) and were on tacrolimus (90.7%), 
mycophenolate (94.0%) and steroid therapy (81.7%) (Table). The genotype frequency 
distribution of TCF7L2 rs7903146 was in accordance with Hardy-Weinberg equilibrium 
(p=0.13). In addition, according to dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7903146), the minor allele 
frequency (MAF) of rs7903146 in the subset of Caucasian patients (39.0%) was similar to that 
reported for Tuscan Italians (HAPMAP-TSI, 38.6%). 
Moreover MDR1 polymorphisms were strongly associated each-other, with a concordance 




Description of the overall population and comparison between patients who developed 
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Table: MDR1 polymorphism correlation 
MDR1 1236: CC 1236: CT 1236: TT total 
3435: CC 2 16 92 110 
3435: CT 25 154 36 215 
3435: TT 75 30 2 107 




Sixty-six patients (14.2%) developed PTDM, after a mean time of 16.2±30.4 months from 
surgery. Incidence of PTDM was 9.25% and 11.03% at 1 and 2 years, respectively. 
The comparison between patients who developed PTDM and those who did not showed that 
KTRs with PTDM were older, had a higher BMI at discharge from KTx and were less likely to 
carry TCF7L2 rs7903146 genotype CC, while no other major differences could be shown 
(Table). Indeed, none of the other study polymorphisms was associated with PTDM. 
As for TCF7L2 rs7903146 genotype (Figure), the 1-year and 2-year-risks were respectively 
5.82% and 7.83% in CC patients, 11.92% and 13.3% in CT patients and 20.47% and 22.74% in 
TT patients (p for trend <0.001). 
However, restricting the analysis to 20/66 (30.3%) patients who were first treated for PTDM 
within 14 days of surgery, TCF7L2 rs7903146 genotype was not a significant risk factor, as 
5/163 (3.1%) patients with a CC genotype, 12/237 (5.1%) with a CT genotype and 3/64 (4.7%) 
with a TT genotype developed this “early-onset” PTDM (p=0.619).  
 
Figure 1. Diabetes-free survival analysis stratified by TCF7L2 rs7903146 genotype (censored 
for graft loss or patient death). Genotype CC is the bold line (n=163), CT is the dashed line 




Description of the overall population and comparison between patients who developed 
diabetes after transplant (PTDM) and those who did not. Values are expressed as 
mean±standard deviation or n (%); p values refer to the comparison between patients with PTDM 











Age (years) 52.4 ± 12.3 55.4 ± 10.2 51.9 ± 12.6 0.008 
 Age > 40 years 385 (83.0) 61 (92.4%) 324 (81.4%) 0.027 
Male 303 (65.3%) 39 (59.1%) 264 (66.3%) 0.252 
Caucasian 452 (97.4%) 64 (97.0%) 388 (97.5%) 0.806 
HCV Positive 31 (6.7%) 4 (6.1%) 27 (6.8%) 0.827 
Ever Peritoneal Dialysis 112 (24.1%) 11 (16.7%) 101 (25.4%) 0.125 
Ever Hemodialysis 388 (83.6%) 59 (89.4%) 329 (82.7%) 0.171 
Peak PRA > 0% 115 (24.8%) 23 (34.8%) 92 (23.1%) 0.041 
Previous transplants 44 (9.5%) 10 (15.2%) 34 (8.5%) 0.090 
Deceased Donor 444 (95.7%) 66 (100%) 378 (95.0%) 0.063 
HLA mismatches > 3 136 (29.3%) 21 (31.8%) 115 (28.9%) 0.634 
Cold ischemia time (hours) 19.3 ± 5.7 20.4 ± 6.5 19.2 ± 5.5 0.085 
BMI (Kg/m2)  24.1 ± 3.4 26.4 ± 3.8 23.7 ± 3.2 <0.001 
 BMI ≥ 25 Kg/m2 183 (39.4%) 42 (63.6%) 141 (35.4%) <0.001 
Delayed Graft Function 103 (22.2%) 19 (28.8%) 84 (21.1%) 0.164 
One or more acute rejection 
episodes 
32 (6.9%) 8 (12.1%) 24 (6.0%) 0.071 
Induction therapy: 
 None 
















































Steroid withdrawal 85 (18.3%) 13 (19.7%) 72 (18.1%) 0.755 
Follow up time (years) 3.97 ± 3.73 4.01 ± 3.93 3.96 ± 3.70 0.463 




Multivariate analysis of risk factors for PTDM 
Among analyzed risk factors, only age, sex, TCF7L2 rs7903146 polymorphism, BMI, previous 
transplants and CIT significantly affected the multivariate risk model (Table). Significant risk 
factors for PTDM were age (per year; HR = 1.029; 95%CI 1.005-1.054), BMI (25.0-29.9 vs 
<25.0, HR = 2.43; 95%CI 1.40-4.23; 30 vs <25.0, HR = 5.70; 95%CI 2.77-11.74), TCF7L2 
rs7903146 (per each T allele; HR 1.807; 95%CI 1.261-2.590) and previous transplants (HR 
2.798; 95%CI 1.388-5.638). When multivariate analysis was limited to Caucasian patients, the 
effect of rs7903146 remained significant. Comparison of multivariate analysis of risk factors 
for PTDM using a dominant and or a recessive model of inheritance of the TCF7L2 rs7903146 
polymorphism showed that the strongest association was found under the recessive model (TT 
vs CC+CT, HR: 2.29, 95%CI: 1.30-4.04, p=0.004). 
 
Multivariate analysis of risk factors for PTDM in renal transplant patients. 
Risk Factor (reference group) HR 95% CI p-value 
   Age (per year) 1.029 1.005-1.054 0.017 
   BMI  
 < 25.0 
 25.0 – 29.9 













   TCF7L2 rs7903146 (per each T 
allele) 
1.807 1.261-2.590 0.001 
   Previous KTx (vs. first KTx) 2.798 1.388-5.638 0.004 
Multivariate analysis adjusted by sex and cold ischemia time (CIT). Variables entered but not retained in the 
model: tacrolimus, cyclosporine A, delayed graft function, acute rejection, panel reactive antibodies, ethnicity. 




Comparison of multivariate analyses of risk factors for PTDM using a dominant or a 
recessive model of TCF7L2 rs7903146 in Caucasian patients.  
 Dominant genetic model Recessive genetic model 
Risk Factor 
(reference group) 
HR 95% CI p-value HR 95% CI p-value 
   Age (per year) 1.029 1.005-1.054 0.019 1.029 1.005-1.054 0.019 
   BMI  
   <25 
   25.0- 29.9 

























   TCF7L2 rs7903146 
(TT+CT vs. CC) 
1.889 1.043-3.419 0.037 - - - 
   TCF7L2 rs7903146 
(TT vs. CT+CC) 
- - - 2.291 1.301-4.036 0.004 
   Previous transplants 
(vs. first KTx) 
2.708 1.343-5.458 0.006 3.087 1.517-6.284 0.002 
HR: Hazard Ratio; Ref: reference; CI: Confidence Interval; BMI: body mass index. 
Multivariate analysis adjusted by sex and cold ischemia time (CIT). 
 
Moreover TCF7L2 rs7903146 was evaluated as an effect modifier of the other risk factors by 
applying the same multivariate risk model in each polymorphism group (CC vs. CT vs. TT), 
and both the hazard ratio and strength of the associations remained the same, even if some risk 
factors lost statistical significance: therefore TCF7L2 rs7903146 polymorphism is not an effect 
modifier of the reported associations. The TCF7L2 rs7903146 polymorphism was also 
evaluated for collinearity with the other risk factors and was not associated with age (p=0.702), 
sex (p=0.618), BMI (p=0.415), previous transplant (p=0.079) and CIT (p=0.389). 
Lastly, we developed a multivariate risk model for PTDM developing after 14 days from 
surgery: both the TT genotype (HR=3.30; 95%CI 1.69-6.44) and BMI (25.0-29.9 vs <25.0, 
HR=2.61; 95%CI 1.22-5.59; 30.0 vs <25.0, HR= 10.99; 95%CI 4.62-26.11) were confirmed 
to be a significant, independent risk factors, while age (HR 1.019; 95%CI 0.99-1.05) and 
previous transplants (HR 2.52; 95%CI 0.85-7.48) did not reach a statistical significance; 
however the parameter estimates were very similar to the general model for PTDM. 
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Comparison with the Verona Cohort 
The Verona cohort consisted in 190 kidney transplant recipients who received their transplant 
in Verona and were included in a genetic study in Verona (50.0 ± 13.4 years, 64.4% males): 
they were mainly Caucasian (96.3%), and received a KTx from a deceased donor (88.3%). The 
genotype frequency distribution of TCF7L2 rs7903146 was in accordance with Hardy-
Weinberg equilibrium (p=0.72). The comparison of risk factors for PTDM between the two 
cohorts is reported in Table: patients from Verona were younger, had less cold ischemia time, 
and were more likely to be obese (BMI > 30). The two cohorts received a different IS therapy, 
as for induction therapy, choice of CNI (much more Cyclosporine in Verona) and use of 
mTOR inhibitors (more common in Verona). 
Table. Comparison between the “Novara gene cohort” and the “Verona cohort” 





Age (years) 52.4 ± 12.3 50.0 ± 13.4 0.033 
Male 303 (65.3%) 122 (64.4%) 0.791 
TCF7L2 rs7903146 C>T 
  CC 
  CT 













Previous transplants 44 (9.5%) 14 (7.3%) 0.388 
 Prev. NOT-kidney Tx 0 4 (2.1%) 0.007 
Cold ischemia time (hours) 19.3 ± 5.7 14.2 ± 5.6 <0.001 
BMI (Kg/m2)  24.1 ± 3.4 24.5 ± 4.2 0.244 
 BMI ≥ 25 Kg/m2 183 (39.4%) 74 (38.9%) 0.907 
 BMI ≥ 30 Kg/m2 26 (5.6%) 21 (11.1%) 0.014 
Acute rejection 32 (6.9%) 11 (5.7%) 0.604 
Induction therapy: 
 None 






































PTDM 66 (14.2%) 13 (6.8%) 0.008 
 Early PTDM (< 14 days) 20 (4.3%) 11 (5.8%) 0.419 




In the Verona cohort 13 patients (6.8%) developed PTDM, which is less than in the Novara 
cohort. However there was no difference between the rate of diagnosis of early diabetes 
(p=0.42), while the two cohorts were significantly different for late PTDM. Indeed, given this 
very low event rate in the Verona cohort (much less than expected), we were not able to 
identify any risk factor for PTDM. Moreover, as the Verona cohort was significantly different 
from the Novara cohort, particularly as for event rate and “late” event rate (only 2 events, 
instead of the expected 20), we were not able to replicate the results obtained from the Novara 
cohort. 
As for the Novara cohort, TCF7L2 rs7903146 genotype was not a significant risk factor for 
early PTDM, as 4/84 (4.8%) patients with a CC genotype, 6/83 (7.2%) with a CT genotype and 
1/23 (4.3%) with a TT genotype developed this “early-onset” PTDM (p=0.754).  
 
 
Meta-analysis of TCF7L2 rs7903146 and risk of PTDM in renal transplant patients  
The electronic search on Web of Knowledge and PubMed yielded a total of 15 articles. After 
exclusion of 10 studies, respectively for overlapping with another included study (n=5), 
irrelevance (n =1), not including renal transplant recipients (n=2), review (n=1) and 
nonresponse of authors to e-mail (n=1), a total of 5 studies fulfilled our inclusion criteria. 
These identified studies were published from 2009 to 2014, and their sample sizes ranged from 
234 to 1076 KTRs, with a percentage of patients with PTDM ranging from 11.0% to 43.9%. In 
all studies, distribution of rs7903146 genotypes was found in Hardy-Weinberg equilibrium (all 












Age at transplantation 











et al (25) 
2009 1076 Mainly 
Caucasian 






Per each T allele,  
OR: 1.60 (1.18-2.25, 
p=0.002) 
29.2 
Kang et al 
(24) 
2009 589 Korean 42.6 ± 9.1 37.4 ± 9.3 1.87  
 
0.32 
at 1 year 
after Tx 
Per each T allele,  






et al (26) 






All patients: NS 
Early onset*: NS 
Late onset: CT+TT, 
OR: 1.88 (0.80-4.24, 
p=0.089) 
23.0 
Yang et al 
(28) 
2011 303 Hispanic 44.3 ± 13.8 41.0 ± 13.1 1.29  
 
0.78 






et al (29) 
2014 427 Caucasian 49.1 ± 13.2 42.4 ± 14.0 1.88  
0.15 
at 1 year 
after Tx 
NS 29.4 
NR, not reported; NS,  not significant; MAF, minor allele frequency.*developed up to 14 days from transplantation;  developed later than 14 
days from transplantation. †Test for departure of TCF7L2 rs7903146 from HWE.  
 
Random-effect meta-analysis combining the present results with data from these previous 
studies (total patients, n=3105) showed a significant relationship between rs7903146 and risk 
of PTDM under the genetic dominant model (CT+TT vs CC, OR: 1.44, 95%CI: 1.06-1.96, 
p=0.019, Figure, panel A) which, however, was limited by the presence of heterogeneity 
among studies (I2=49%, P=0.08). Conversely, a highly significant association was found with 
rs7903146 under the recessive model (TT vs CT+CC, OR:1.95, 95%CI 1.39-2.74, p=0.0001, 
Figure, panel B) in the absence of study heterogeneity (I2= 0%, P=0.45). Given that minor 
allele frequency (MAF) of rs7903146 differs between European and Asian populations 
(http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7903146), we conducted a 
sensitivity analysis restricted to Caucasians which confirmed the stability and liability of the  
association (TT vs CT+CC,  OR: 1.93, 95%CI, 1.32-2.80, p<0.001). 
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In addition, we also conducted a meta-regression analysis to assess the impact of MAF on the 
association of rs7903146. A trend towards a linear relationship was found between OR and MAF 
of rs7903146 under the recessive model (p=0.089). No evidence of publication bias was found 
under either the dominant (Egger’s test p=0.55) or the recessive (Egger’s test p= 0.72) contrast 
of rs7903146. 
 
Figure - Forest plots for the association of TCF7L2 rs7903146 with risk of PTDM in the 
dominant (CT+TT vs CC, Panel A) or recessive (TT vs CT+CC, Panel B) mode of 
inheritance. Pooled estimates (OR, odds ratio) are from the random-effects model. 
 
 
Predictive value of risk factors and models on PTDM  
By using the area under the Receiver Operating Characteristic curve (AUC) and Youden´s 
index, age 56 was found as optimal cutoff value for PTDM prediction. Regarding BMI, 
patients were classified in three groups: BMI <25, 25 BMI <30 (this BMI interval defines an 
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overweight person), BMI  30 (this value of BMI defines an obese subject). Then, we 
compared three potential predictive risk models for PTDM based on the variables identified as 
significant predictors in the multivariate analysis (Table): Model 1 included only the three 
clinical factors (age, BMI and previous transplants), Model 2 additionally included rs7903146 
in a dominant model (CT+TT vs CC) and Model 3 additionally included rs7903146 in a 
recessive model (TT vs CT+CC).  
 
Table. Coefficients and risk points of each predictor of PTDM for risk prediction models. 













Model 1 (clinical factors only) Model 2 (clinical factors and dominant model 
of rs7903146) 
Model 3 (clinical factors and recessive model of 
rs7903146) 















































































































































































Only Model 3 displayed a significantly better predictive ability than Model 1 (0.75 vs 0.71, 
P=0.013), suggesting that rs7903146 can improve the predictive ability of a model based on 
clinical variables in the recessive but not in the dominant model (Figure).  
Indeed, when applying the score developed in Model 3, the proportion of patients with PTDM 
in each score group (from 0 to 5) generally showed an increasing trend from lower to higher 
scores (Figure): 4.0% (score 0), 7.5% (score 1), 27.2% (score 2), 38.5% (score 3), 40.0% (score 




Figure - The area under the ROC curve (AUROC) for three PTDM risk-predicting models 
calculated by the risk score method. Model 1 includes clinical factors only (age, BMI and 
previous transplantation); Model 2 contains clinical factors and the dominant model of 
rs7903146 (CT+TT vs CC); Model 3 considers clinical factors and the recessive model of 
rs7903146 (TT vs CT+CC).   
 
 
Figure - Proportion of patients with (black bar) and without (white bar) post-transplant 





Specific Aims: to evaluate the impact of different therapies (treated as “environmental” risk 
factors) on post-transplant thrombotic events (early events). 
Overall 911 patients (51.2 ± 12.5 years, 62.8% males) underwent KTx (Table): 326 of them (39.5%) 
were on single antiplatelet therapy at the time of surgery, of which 266 (81.6%) on aspirin, 40 (12.3%) 
on ticlopidine, 1 (0.3%) on clopidogrel and 19 (5.8%) on dipiridamole. Moreover 12 (1.5%) patients 
were on a dual antiplatelet therapy (aspirin plus ticlopidine) and 37 (4.5%) were on oral anticoagulant 
therapy, of which 2 were also on aspirin. 
Secondary prevention of CVE was an indication for single AAT in 79/326 patients (24.2%), primary 
prophylaxis of CVEs in 192/326 (58.9%) and vascular access patency preservation in 55/326 (16.9%), 
while a dual AAT was used as secondary prophylaxis after a previous CVE in 8 (66.7%) and for 
vascular access patency in 4 (33.3%). VKA was indicated for atrial fibrillation (chronic or paroxysmal) 
in 15/37 patients (40.5%), as a secondary prophylaxis after repeated thrombotic events or known 
thrombophilia in 11/37 patients (29.7%), for the presence of a mechanic heart valve in 6/37 patients 
(16.2%) and for other indications (mainly vascular access patency) in 5/37 (13.5%). Immediately before 




Table - Description of the overall enrolled population. Values are 
expressed as mean±standard deviation or n/tot (%) 
Parameter Overall population 
(n=911) 
Age (years) 51.2 ± 12.5 
Male 572/911 (62.8%) 
Duration of dialysis (years)  4.5 ± 3.8 
Deceased Donor 872/911 (95.7 %) 
Dual deceased donor KTx 47/911 (5.1 %) 
Transplant year 
1998 – 2003 
2004 – 2008 





BMI (Kg/m2)  23.9 ± 3.5 
PTH at transplant (pg/mL) 177.8 ± 178.2 
Cinacalcet at transplant 56/893 (6.3%) 
Parathyroidectomy before KTx  96/893 (10.7%) 
HCV Positive 82/911 (9.0 %) 
Diabetes at KTx 51/903 (5.6%) 
Previous CVE 
 Myocardial infarction 








Delayed Graft Function 215/896 (24.0 %) 
One or more acute rejection episodes 84/635 (13.2 %) 
Serum creatinine at discharge (mg/dL)  2.1 ± 0.9 
eGFR at discharge (ml/min/1.73m2) 39.3 ± 17.7 
Induction therapy: 
 None 




















PTH: parathormone; BMI: body mass index; KTx: kidney transplant; CVE: cardiovascular event; eGFR: 
estimated Glomerula Filtration Rate (CKD-EPI equation); ATG: anti-thymocyte globulin 
 
Patients on AAT or VKA were older and were more likely to have had a CVE before KTx; moreover,  
they had a higher incidence of delayed graft function, and received more blood transfusions after KTx. 
Immunosuppressive therapies were not different if the patients were stratified by AAT or VKA. 
After surgery, AAT was resumed after a mean period of 240 ± 434 days in patient on primary 
prevention and 91 ± 119 days in patient on secondary prevention. Oral anticoagulation was resumed at 
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84.7 ± 87.5 days, but a bridge therapy with low molecular weight heparin (LMWH) was performed as 
detailed above. 
 
Table - Comparison between patients on pre-transplant antiaggregant therapy, oral anticoagulant 







Neither AAT or 
VKA 
(n=538) 
Age (years)  55.0 ± 11.4 * 53.1 ± 10.4 * 48.9 ± 12.5 
Male 221/336 (65.7%) 24/37 (64.9%) 327/538 (60.8%) 
Duration of dialysis (years)  4.0 ± 3.6  7.6 ± 5.1 * § 4.4 ± 3.7 
Deceased Donor 329/337 (97.6%) * 36/37 (97.3%) 507/538 (94.2%) 
Transplant year 
1998 – 2003 
2004 – 2008 













Diabetes at KTx 32/336 (9.5%) * 3/37 (8.1%) 16/538 (3.0%) 
Previous CVE 87/336 (25.9%) * 29/37 (78.4%) * § 40/538 (7.4%) 
Delayed Graft Function 95/336 (28.2%) * 16/37 (43.2%) * 104/538 (19.3%) 
One or more acute rejections 35/253 (13.8%) 6/23 (26.1%) * 43/359 (12.0%) 
Length of hospital stay (days)  25.0 ± 15.9 33.4 ± 21.9 * § 24.1 ± 17.3 
Creatinine at discharge (mg/dL) 2.2 ± 0.8 * 2.4 ± 0.8 * 2.0 ± 0.9 
eGFR at discharge (ml/min/1.73m2) 35.8 ± 15.1 * 31.7 ± 11.0 * 42.1 ± 19.2 
Blood units per patient 2.3 ± 2.8 * 4.0 ± 4.4 * 1.7 ± 2.6 
Early hemorrhagic events 9/336 (2.7%) § 4/37 (10.8%) * 8/538 (1.5%) 
Early post-transplant CVE  15/336 (4.5%) § 5/37 (13.5%) * 12/538 (2.2%) 
AAT: antiaggregant therapy; VKA: oral anticoagulation with vitamin K antagonist; eGFR: estimated Glomerula Filtration Rate 
(CKD-EPI equation); KTx: kidney transplant; CVE: cardiovascular event; ATG: anti-thymocyte globulin; * p < 0.05 vs. no AAT 
neither VKA;§ p < 0,05 of AAT vs. VKA. 
 
Over the first 90 days after KTx CVE occurred in 32/911 (3.5%), including 12 graft artery or vein 
thrombosis, 5 graft infarctions and 8 AMI. 
Among them, 3 (9.3%) were fatal (2 cardiogenic shock in the early post-KTx hours, one mesenteric 
artery thrombosis) and 11 led to graft loss (34.4%) for graft thrombosis. The other 18 included  8 
myocardial infarctions, 6 transplant infarctions, 3 angina episodes and one ischemic stroke. Among 
patients with a post-KTx CVE, 15/32 (46.9%) were on a single AAT (13 on acetylsalicylic acid and 2 
on ticlopidine), 5/32 (15.6%) were on VKA; none was on dual AAT. Screening for genetic and acquired 
thrombophilia was performed in 16 patients with a post-KTx CVE and resulted positive in two: one 




At univariate analysis, risk factors for early CVE were age, KTx year, PTH, cinacalcet use at transplant, 
previous CVE and VKA at transplant, while AAT use was not associated with CVE (Table). 
Interestingly, even if PTH and cinacalcet were, parathyroidectomy was not significantly associated with 
CVE (OR=1.816; 95%CI=0.624-5.286; p= 0.270). Significant independent risk factors for CVE at 
multivariate analysis were previous CVE (OR 4.180, p = 0.0032) and cinacalcet use at time of KTx (OR 
7.930, p < 0.0001) (Table 4).  
Patients with a post-KTx CVE were more likely to have a DGF (42.9% vs. 23.5%, p = 0.041), to 
receive a higher number of transfusions during hospitalization (4±3.2 vs. 2.1±3.4, p < 0.0001) and to 
have a higher serum creatinine at discharge (2.6±1.1 vs. 2.0±0.8 mg/dL, p = 0.012). 
 
Table - Univariate and multivariate logistic model for major early CVE (n=32) in the overall 
population (n=911). 
Univariate analysis OR 95% CI p-value 
Age (for 1 year increase) 
Transplant year 2009-2013 (vs 1998-2003) 
 Transplant year 2004-2008 (vs 1998-2003) 
PTH more than 187 pg/mL (vs less 187 pg/mL) 
Cinacalcet use at transplant (vs no cinacalcet) 
History of CVE (vs no previous CVE) 
VKA at transplant (vs no VKA and no AAT) 










1.526 – 13.684 
0.577 – 5.993 
1.377 – 10.268 
3.553 – 21.866 
2.156 – 9.149 










Multivariate analysis OR 95% CI p-value 
Transplant year 2009-2013 (vs 1998-2003) 
 Transplant year 2004-2008 (vs 1998-2003) 
Cinacalcet use at transplant (vs no cinacalcet) 





0.380 – 26.513 
0.448 – 30.531 
3.002 – 20.945 





PTH: parathormone; CVE: cardiovascular event; VKA: oral anticoagulation with vitamin K antagonist; AAT: 







Thrombosis and mTORi 
Specific Aims: to evaluate the impact of different therapies (treated as “environmental” risk 
factors) on post-transplant thrombotic events (late events). 
167 received an mTOR-I and were followed for a total time of 985 pt-years (mean 5.73±3.25 yrs), 
while the total time on mTOR-I therapy was 575 pt-years (mean 3.34±2.57 yrs). No major clinical 
differences were noted between patients on mTOR-I and those who never received them; however 
patient who received and mTOR-I were slightly older at the time of transplant (51.4 ± 10.8 vs 50.5 ± 
13.4 years, p = 0.036). Among mTOR-I treated patients, the other most common IS was with tacrolimus 
(81/167=48.5%), followed by mycophenolate (65/167=38.9%). 47 pts (28.1%) suspended the mTOR-I, 
of which 23 (49%) due to major adverse events, while the others for infections or minor adverse events. 
 











Age (years) 51.06±12.78 50.62±13.41 52.45±10.78 0.036 
Male (%) 442 (63.7) 334 (63.4) 108 (64.7) 0.762 
Sirolimus, at any time 119 (17.1) 0 119 (71.3) n/a 
Initial therapy with SRL (%) 26 (3.7) 0 26 (15.6) n/a 
Initial therapy with EVER (%) 26 (3.7) 0 26 (15.6) n/a 
Initial therapy with TAC (%) 610 (87.9) 492 (93.4) 118 (70.7) <0.001 
Initial therapy with CsA (%) 60 (8.6) 27 (5.1) 33 (19.8) <0.001 




During the follow-up, there were globally 59 MTE (8.5%), of which 35 (5.0% of patients) were 
arterial and 24 (3.5% of patietns) venous events. Among patients who ever received an mTOR-I, 16 
events occurred during mTOR-I therapy (9.58%; M:F=11:5; males=68.8%, one lethal event), while 8 
events occurred during the other mTOR-I free periods (4.79%; M:F=5:3; males=62.5%). 
The overall incidence rate of MTE was of 1.496 events per 100 pt-year: 2.783 during mTOR-I 
therapy and 1.277 while not on mTOR-I. The incidence rate ratio was 2.180 (95% confidence interval: 
1.228–3.870, p = 0.003) with a mean incidence rate difference of 1.507 more events per 100 pt-year 
during mTOR-I. 
MTEs occurred at a mean age of 57.30±8.39 years and at 4.28±3.79 years after starting mTOR-I 
therapy (range: 7 days – 10.8 years). Among these patients, six were tested for acquired and genetically 
inherited causes of thromhophilia and one (1116 = 63%) resulted positive for an heterozygous mutation 
of factor V Leiden, as reported previously. 
 
Table – Follow up events of patients who ever received an mTOR-I and those who did not 





Follow up time (years) 5.61±3.92 5.73±3.25 0.355 
Time on mTOR-I - 3.34±2.57 n/a 
Dead at the last follow up (%) 13 (2.5) 10 (5.9) 0.027 
 CV death (%) 8 (1.5) 3 (1.8) 0.802 
Major thrombotic events (%) 35 (6.6) 24 (14.4) <0.001 
 Venous events (%) 14 (2.7) 10 (6.0) 0.040 
 Arterial events (%) 21 (4.0) 14 (8.4) 0.024 
CVE incidence rate (ev/100-pt-yrs) 1,277 2,783 0,003 
 Venous CVE inc. rate 0,511 1,160 0,023 
 Arterial CVE inc. rate 0,766 1,623 0,040 





Pts on mTOR-I with MTE did not experience more malignancies needing switch to mTOR-I (33.3% 
versus 46.8%, p 0.520): particularly only one patient on mTOR-I developed a DVT during 
chemotherapy for lymphoma. Interestingly patients on mTOR-I who developed a MTE had a 
significantly longer duration of mTOR-I therapy (5.82±3.48 vs 3.19± 2.47 years; p=0.003), as 
compared to pts on mTOR-I without MTE, suggesting that they have been exposed to the same risk for 
a longer time. 
Table – Comparison of patients on mTOR-i who developed a major thrombotic event (MTE) 
and those on mTOR-i who did not develop an MTE. 







Age (years) 53.02±9.80 52.39±10.88 0.404 
Male (%) 11 (68.8) 97 (64.2) 0.720 
Follow up (years) 6.98±3.47 5.59±3.23 0.064 
Initial therapy with SRL (%) 7 (43.8) 19 (12.6) 0.001 
Initial therapy with EVER (%) 3 (18.8) 23 (15.2) 0.712 
Malignancy or history of malign. (%) 2/6 (33.3)  51/109 (46.8) 0.520 
Time of switch to mTOR-I (mo) 6.85±14.00 21.95±30.2 0.991 
Sirolimus as maintenance (%) 12 (75.0) 107 (70.9) 0.728 
Sirolimus dose (mg/day) 1.70±0.95 1.52±0.85 0.267 
Sirolimus BTL (ng/mL) 6.64±1.58 6.73±1.48 0.574 
Everolimus dose (mg/day) 1.25±0.66 1.84±0.70 0.95 
Everolimus BTL (ng/mL) 4.7±1.21 5.59±1.52 0.917 




Ischemic heart disease 
Specific Aims: To evaluate if SNPs associated with IS metabolism or complications may indeed 
alter the risk of thrombotic or cardiovascular events. To develop a risk model for specific post-
transplant CVE based on pre-transplant variables. 
We included 506 non-diabetic patients (age: 52.4 ± 12.2 years; 64.4% males), who received a 
KTx from a deceased donor (95.3%) and were on tacrolimus (90.9%), mycophenolate mofetil 
(MMF) or mycophenolic acid (MPA) (94.5%) and steroid therapy (82.6%) (Table).  
Twenty-two patients (4.3%) developed CAD, after a mean time of 27.2 ± 40.1 months from 
surgery. Incidence of CAD was 3.1% and 5.3% at 1 and 5 years, respectively. 
The univariate comparison between patients who developed a CAD and those who did not 
showed that KTR who developed a post-transplant ischemic heart event were more likely to 
have suffered from a cardiac ischemic event before KTx (p<0.001), to be on an anti-platelet 
therapy (p=0.013) and to have a higher number of total HLA mismatch (p=0.041) (Table). A 
non-significant trend of association was found for years on dialysis (p=0.105), statin therapy at 
KTx (p=0.095), and DGF (p=0.095). Even if non-statistically significant, 2/22 (9.1%) patients 
with a post-KTx CAD died during follow-up after the event, as compared to 8/484 (1.7%) of 
those who did not develop it (p=0.315). None of the other clinical parameters evaluated were 
found related in the univariate analysis to post-transplant CAD, including age, sex, renal 




Description of the overall population and comparison between patients who developed post-
transplant ischemic heart event (CAD) and those who did not. Values are expressed as 













Age (years) 52.4 ± 12.2 52.8 ± 9.4 52.4 ± 12.4 0.867 
Male 64.4% 72.7% 64.0% 0.678 
Years on dialysis 4.00 ± 3.68 5.57 ± 4.45 3.93 ± 3.60 0.105 
Peak PRA > 20% 8.3% 9.1% 8.3% 0.891 
Previous transplants 9.1% 9.1% 9.1% 1 
Deceased Donor 95.3% 100% 95.0% 0.274 
Total HLA mismatches  2.87 ± 1.04 3.18 ± 0.66 2.86 ± 1.05 0.041 
BMI (Kg/m2)  24.1 ± 3.46 24.5 ± 2.99 24.0 ± 3.48 0.536 
Parathormone at KTx (pg/mL) 190.0 ± 186.0 223.2 ± 257.9 188.3 ± 182.3 0.547 
Parathyroidectomy 10.7% 9.5% 10.9% 0.806 
MGUS at KTx 3.4% 9.1% 3.1% 0.127 
Ever smoker 56.3% 76.5% 55.1% 0.101 
Hypertensive 83.8% 78.9% 84.1% 0.396 
Any previous cardiovascular event 17.7% 42.9% 16.6% 0.003 
      Previous ischemic heart event 8.5% 38.1% 7.3% <0.001 
      Previous stroke 1.6% 4.8% 1.5% 0.254 
On antiaggregant therapy at KTx 42.8% 71.4% 41.6% 0.013 
LDL-cholesterol (mg/dL) 114.6 ± 32.2 107.5 ± 36.7 115.0 ± 32.0 0.565 
On statin at KTx 25.3% 44.4% 25.1% 0.095 
Delayed Graft Function 21.9% 36.4% 21.3% 0.095 
One or more acute rejection episodes 10.2% 11.1% 10.2% 0.875 
Induction therapy: 
 None 











































Serum Creatinine at discharge 
(mg/dL) 
2.06 ± 0.94 2.13 ± 0.75 2.07 ± 0.94 0.713 
eGFR at discharge (mL/min/1.73m2) 40.0 ± 19.6 37.1 ± 16.3 40.1 ± 19.8 0.410 
Follow up time (years) 3.78 ± 3.73 5.01 ± 3.67 3.72 ± 3.72 0.121 
BMI: body mass index; KTx: kidney transplant; MGUS: monoclonal gammopathy of unknown 
significance; ATG: anti-thymocyte globulin; IS: immunosuppressive.  
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Among studied SNPs, only the TCF7L2 rs7903146 seemed to be associated with the risk of 
post-transplant ischemic heart events. The genotype distribution of TCF7L2 rs7903146 was in 
accordance with Hardy-Weinberg equilibrium (p=0.23). As for TCF7L2 rs7903146 genotype 
(Figure), the 1-year and 5-year-risks were respectively 0.8% and 0.8% in CC patients, 3.6% 
and 7.2% in CT patients and 7.2% and 9.7% in TT patients. A significant association of 
rs7903146 was found with post-transplant CAD using the Armitage trend test for an additive 
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Ischemic heart event-free survival analysis of non-diabetic patients stratified by TCF7L2 
rs7903146 genotype (censored for graft loss, patient death or PTDM diagnosis). Genotype 
CC is the bold line (n=178), CT is the dashed line (n=255) and TT is the dotted line (n=73). Log-
rank test has a p<0.001. 
 
 
Evaluation of collinear variables with respect to TCF7L2 rs7903146  
We also investigated whether any of the known risk factors for CAD were associated with the 
TCF7L2 rs7903146 T allele in our population (Table). Indeed, cardiovascular events prior to 
KTx are not associated with this polymorphism in KTRs. Moreover, specific pre-transplant 
cardiovascular events and other traditional (hypertension, dyslipidemia, age, sex, BMI, 
previous smoking habit, renal function) and non-traditional risk factors (years on dialysis, 
parathormone, IS therapy, DGF, acute rejection episodes, HLA mismatches, and MGUS) were 
uniformly distributed among study groups. Moreover, patients carrying the TT genotype had 
actually a higher rate of PTDM (27.4% vs. 11.9%; p<0.001), but as these patients were 
censored from the main analysis at the time of PTDM diagnosis, PTDM cannot be considered a 
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confounder of the observed association. Moreover, PTDM risk associated with this TCF7L2 
polymorphism was not affected by the presence of a CAD event. 
 
Table - Comparison between TCF7L2 rs7903146 genotypes in the study cohort. Values are 
expressed as mean±standard deviation or %; p values refer to the comparison between patients 








Age (years) 52.1 ± 13.3 52.6 ± 11.6 52.5 ± 11.8 0.908 
Male 62.4% 65.1% 67.1% 0.736 
Years on dialysis 4.05 ± 3.60 3.63 ± 3.34 4.09 ± 3.84 0.351 
Ever on hemodialysis 82.0% 80.0% 84.9% 0.613 
Ever on peritoneal dialysis 24.7% 25.9% 20.5% 0.648 
Peak PRA > 20% 9.7% 7.3% 8.2% 0.687 
Previous kidney transplants 5.6% 11.7% 8.2% 0.088 
Deceased Donor 95.5% 94.5% 97.3% 0.610 
Total HLA mismatches  2.96 ± 1.06 2.83 ± 1.04 2.82 ± 1.00 0.429 
Cold ischemia time (hours) 19.0 ± 5.5 19.4 ± 5.6 19.6 ± 6.2 0.689 
BMI (Kg/m2)  24.0 ± 3.3 24.2 ± 3.5 23.6 ± 3.8 0.389 
Parathormone at KTx (pg/mL) 185 ± 182 191 ± 185 198 ± 199 0.864 
Parathyroidectomy 12.4% 9.8% 9.6% 0.623 
MGUS at KTx 2.2% 4.3% 2.7% 0.477 
Ever smoker 55.4% 56.5% 57.4% 0.966 
Hypertensive 86.3% 80.5% 89.1% 0.113 
Any previous cardiovascular event 18.5% 17.3% 15.7% 0.802 
      Previous ischemic heart event 11.2% 6.7% 8.2% 0.243 
      Previous stroke 1.1% 2.4% 0% 0.303 
On anti-platelet therapy at KTx 46.9% 40.5% 40.8% 0.377 
On statin at KTx 27.7% 21.3% 21.7% 0.399 
LDL-cholesterol (mg/dL) 119 ± 31 111 ± 31 115 ± 37 0.250 
Delayed Graft Function 21.9% 20.4% 24.7% 0.729 
One or more acute rejection episodes 8.5% 8.3% 12.5% 0.616 
Induction therapy: 
 None 











































Serum Creatinine at discharge (mg/dL) 2.04 ± 0.94 2.08 ± 0.84 2.09 ± 1.20 0.885 
eGFR at discharge (mL/min/1.73m2) 35.4 ± 20.4 32.4 ± 15.6 32.5 ± 14.0 0.170 
Follow-up time (years) 3.69 ± 3.66 3.71 ± 3.72 4.20 ± 3.90 0.579 
PTDM 8.4% 14.1% 27.4% <0.001 
BMI: body mass index; KTx: kidney transplant; MGUS: monoclonal gammopathy of unknown significance; ATG: anti-
thymocyte globulin; IS: immunosuppressive; PTDM: post –transplant diabetes mellitus. 
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Multivariate analysis of risk factors for CAD 
In the multivariate Cox analysis, previous cardiac ischemic events (HR: 8.69, 95%CI: 3.57-
21.16, p<0.001), TCF7L2 rs7903146 polymorphism (for each T allele, HR: 2.99, 95%CI: 1.62-
5.52, p<0.001), DGF (HR: 2.42, 95%CI: 0.98-5.95, p=0.056) and HLA-mismatches (for each 
mismatch: HR: 1.55, 95%CI: 1.00-2.43, p=0.053) were independent predictors of post-
transplant cardiac ischemic events. In addition, rs7903146 emerged as independent predictor of 
post-transplant ischemic cardiac events in both the subgroup of patients with (HR=4.10; 
95%CI: 1.13-14.86; p=0.033) and without (HR=3.33; 95%CI: 1.44-7.69; p=0.005) previous 
cardiac events: therefore TCF7L2 rs7903146 polymorphism is not an effect modifier of the 
reported associations.  
 
Table – Multivariate Cox model of risk factors for post-transplant ischemic heart 
events. 
Risk Factor (reference group) HR 95% CI p-value 
TCF7L2 rs7903146 (for each T allele) 2.99 1.62-5.52 <0.001 
Previous cardiac ischemic event 8.69 3.57-21.16 <0.001 
Delayed graft function 2.42 0.98-5.95 0.056 
HLA-mismatches (for each mismatch) 1.55 1.00-2.43 0.053 
HR: Hazard Ratio; CI: Confidence Interval. 
Included but not retained in the model: age, sex, time on dialysis, statin use at time of transplantation. 
 
Lastly, to evaluate the predictive accuracy of the multivariate model, we performed a receiver 
operating characteristic (ROC) curve analysis, using as independent variable the sum of beta-
coefficients associated to each risk factor. This curve was compared to a similar “ad hoc” 
model including the same clinical variables (previous ICE, DGF and HLA mismatches), but 
without the TCF7L2 rs7903146 polymorphism. The area under the ROC curve (AUROC) of 
the model including clinical variables and TCF7L2 polymorphism was 0.790 (95%CI: 0.701-
0.879; p=0.001). The mean sum of beta-coefficients of this model was 2.55 ± 1.13 (min-max 
range: 0-6.11). A model developed including the same clinical variables, but not the TCF7L2 
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polymorphism, showed a lower area under the ROC curve (0.678; 95%CI: 0.561-0.795) as 
compared to the model including the TCF7L2 polymorphism (p=0.003, DeLong’s test). 
 
Figure – ROC curves of the model including TCF7L2 (dashed line) and only clinical 





How much genes and viruses determine viral-related malignancies? 
Overall, 1040 KTx mainly from deceased donors (94.2%) were performed in 1028 patients 
(51.3±12.5 year-old, 63.6% males). During a mean follow up of 4.45±3.9 years after KTx, we 
observed 130 NMSC and 80 non-cutaneous malignancies (NCM) in 66 and 71 patients 
respectively. Among NCM, 18 α-HPV related lesions were observed in 12 patients, who were 
mainly young female patients 84.6% (43.4 ± 7.5 year-old).  
Table. Baseline characteristics of the cohort of 1040 kidney transplant 
recipients (KTRs). Variables are expressed as mean ± St dev or %. 
Age at KTx 51.3 ± 12.5 
Sex (Male) 661/1040 (63.6) 
Ethnicity (Caucasian) 1005/1040 (97.1) 







  90/1040 (8.7) 
    9/1040 (0.9) 
Living Donor 60/1040 (5.8) 
HCV (Positive) 86/1040 (8.3) 
Pre-Transplant Diabetes 65/1040 (6.3) 
Body Mass Index 24.0 ± 3.5 
Peak Reactive Antibodies > 0% 294/1040 (29.3) 


















  93/1040 (8.9) 
934/1040 (89.8) 
  15/1040 (1.4) 
  46/1040 (4.4) 
  35/1040 (3.4) 
Delayed graft function 234/1025 (22.8) 
One or more acute rejection episodes 91/1040 (8.8) 
Creatinine at hospital discharge (mg/dL) 2.05 ± 0.85 




The incidence of NMSC was 1.1%, 7.1%, and 11.8% at respectively 1, 5, and 10 years after 
transplant. The cumulative incidence of malignancy of the kidney or urinary tract was 0.4%, 
1.3%, and 1.6% at respectively 1, 5, and 10 years after transplant, while the cumulative 
incidence of the first alpha-HPV related tumor was 0.5%, 1.8%, and 1.8% at respectively 1, 5, 
and 10 years. The mean time from transplant to the first lesion was 4.2 ± 2.8 years for NMSC, 
3.7 ± 3.3 years for NCM overall, 3.2 ± 3.1 years for alpha-HPV related lesions, and 3.4 ± 3.6 
years for tumors of the kidney or urinary tract. 
 









Figure – Cumulative incidence function (CIF) of NMSC. X-axis: years from KTx 
 
 








When comparing patients without any malignancy with those with malignancies, only age was 
associated with a greater risk of NCM (HR=1.305 for each 10-year increase; 95%CI: 1.072-
1.583; p=0.007) and NMSC (HR=1.913 for each 10-year increase; 95%CI: 1.524-2.389; 
p<0.001), while no other major differences were revealed. Moreover, the use of azathioprine 
was associated with both alpha-HPV lesions (HR=6.38, 95%CI: 1.31-30.96; p=0.022) and 
NMSC (HR=2.76, 95%CI: 1.09-6.95; p=0.032). No other variable was associated with specific 
malignancies, but creatinine at discharge was significantly lower in patients with alpha-HPV 
lesions (p=0.029): this could reflect a young donor age (as donor and recipients are matched 




Table. Description of patients who developed different virus-related tumors after 






















Age at KTx 42.7 ± 7.5 49.8 ± 10.6 57.1 ± 9.3 52.9 ± 10.9 51.1 ± 12.6 
Sex (Male) 1/12 (8.3) 12/13 (92.3) 44/66 (66.7) 42/71 (59.2) 619/969 (63.9) 
Ethnicity (Caucasian) 11/12 (91.7) 13/13 (100) 66/66 (100) 70/71 (98.6) 935/969 (97.0) 

















































Living Donor 0/12 (0) 1/13 (7.7) 0/66 (0) 1/71 (1.4) 59/969 (6.1) 
HCV (Positive) 0/12 (0) 0/13 (0) 2/66 (3.0) 5/71 (7.0) 81/969 (8.4) 
Pre-Transplant Diabetes 0/12 (0) 0/13 (0) 3/66 (4.6) 3/71 (4.2) 62/969 (6.5) 
Body Mass Index 22.7 ± 4.3 23.0 ± 3.1 23.8 ± 3.1 23.7 ± 3.2 24.0 ± 3.6 
Peak Reactive Antibodies > 0% 6/12 (50.0) 4/13 (30.8) 21/65 (32.3) 23/69 (33.3) 271/969 (29.1) 



































































Delayed graft function 0/12 (0) 2/13 (15.4) 17/66 (25.8) 13/71 (18.3) 221/954 (23.2) 
One or more acute rejection 
episodes 
3/12 (25.0) 1/13 (7.7) 4/66 (6.1) 10/71 (14.1) 81/969 (8.4) 
Creatinine at hospital discharge 
(mg/dL) 
1.48 ± 0.51 2.05 ± 0.62 2.10 ± 0.75 1.98 ± 0.69 2.05 ± 0.87 
 
HPV: Human Papilloma Virus; NMSC: non-melanoma skin cancer; KTx: Kidney Transplant; HCV: Hepatitis C; rATG: Thymoglobulin 
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Pharmacogenetics of malignancies 
Specific Aims: To evaluate if SNPs associated with IS metabolism or complications may indeed 
alter the risk of virus-related malignancies. 
Among KTR of the Novara cohort, 430 were analyzed to evaluate the association between 
study SNPs and the occurrence of malignancies. Even if we included both newly transplanted 
patients and older prevalent KTRs (leading to a potential selection bias in this latter group), 
this sample is well representative of the entire Novara cohort. Even if age and 
immunosuppressive therapy are statistically different, the difference can not be considered as 
clinically significant (ie: 1.4 years older at the time of KTx). 
 
Table. Comparison between the whole Novara cohort and the sample who was genotyped 
(Novara-gene cohort). Variables are expressed as mean ± St dev or %. 
  Whole Novara cohort Novara “gene” cohort P 
(n=1040) (n=430) 
Age at KTx 51.3 ± 12.5 52.7 ± 12.4 0.002 
Sex (Male) 661/1040 (63.6) 282/430 (65.6) 0.255 
Ethnicity (Caucasian) 1005/1040 (97.1) 416/430 (96.8) 0.869 
Previous Transplants 100/1040 (9.6) 43/430 (10.1) 0.724 
Living Donor 60/1040 (5.8) 19/430 (4.4) 0.117 
Pre-Transplant Diabetes 65/1040 (6.3) 25/430 (5.7) 0.626 
Body Mass Index 24.0 ± 3.5 24.2 ± 3.4 0.119 
Total HLA Mismatches 2.86 ± 1.04 2.90 ± 1.02 0.295 
Induction Therapy      
 None   89/1040 (8.6)   32/430 (7.4)  
 Basiliximab 797/1040 (76.6) 354/430 (82.3)  
 rATG 154/1040 (14.8) 44/430 (10.3) 0.001 
Manteinance Therapy      
 Tacrolimus 911/1040 (87.6) 390/430 (90.6) 0.011 
 Mycophenolate 934/1040 (89.8) 400/430 (93.1) 0.004 
 Sirolimus or Everolimus   81/1040 (7.8) 30/430 (7.0) 0.412 
Delayed graft function 234/1025 (22.8) 108/430 (25.0) 0.090 
One or more acute rejection 
episodes 
91/1040 (8.8) 55/430 (12.8) <0.001 
Follow up (years) 4.5 ± 3.9 4.3 ± 3.7 0.159 




In this sub-cohort we observed 22 patients with a NMSC, 18 with a NCM, of which 8 had a 
PTLD, corresponding respectively to an affected patient rate of 5.1% (vs. 6.3% in the whole 
cohort), 4.2% (vs. 6.8%) and 1.9% (vs. 1.3%). 
None of the study SNPs was significantly associated with NCM occurrence.  
There was not any statistically significant association between study SNPs and NMSC; 
however a trend was observed as for CYP3A5 *1 carriers (fast CNI metabolism) did not 
develop any NMSC (p=0.077). Moreover, even if not statistically significant, CYP3A4 
rs35599367 T carriers (slow CNI metabolism) had a more than double risk of NSMC as compared to 
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Interestingly virus-related malignancies, including solid, hematologic and cutaneous virus-
related malignancies, (n=32) were all observed among CYP3A5 *3/*3 homozygous (p=0.031). 
Moreover this group had more commonly CMV reactivations post-KTx (p=0.005) in patients 
not receiving an ATG induction therapy, which is so strongly associated to CMV reactivation 
that nowadays patients on this therapy undergo a six months CMV-prophylaxis with 
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valgancyclovir. Indeed CYP3A5 *3/*3 homozygous patients did not significantly differ from 
*1 carriers for all other clinical variables, as reported in table. 
Table – Comparison of patients carrying a CYP3A5 *1 genotype (fast 
metabolizers) and those without (3/3) 





Male 57,1% 67.4% 0,22 
Age 52,0±12,2 52,7±12,7 0,36 
CMV reactivation 3,2% 22,5% 0,005 
Creat 6 mo 1,72±0,56 1,78±0,66 0,29 
BPAR 14.3% 13.0% 0.81 
FK 85,7% 92,2% 0,12 
MMF 88,1% 93,1% 0,20 
mTORi 7,1% 7,5% 0,61 
CMV Ab Positive 88,1% 82,5% 0,252 
PTDM 7,7% 13,3% 0,255 
Coron. A. Dis. 1,9% 5,9% 0,235 
Stroke 1,9% 0,8% 0,418 
Other CV Event 11,5% 14,6% 0,556 
CMV: cytomegalovirus, BPAR: biopsy proven acute rejection; PTDM: post-transplant diabetes; CV: cardiovascular 
As the most associated malignancy to these polymorphism were PTLDs and risk factors for 
PTLDs are not known we investigated more deeply this association. Indeed the following 
SNPs were associated with PTLDs, as shown in table:  















TCF7L2 rs7903146: TT CC or CT 4.26 1.00-18.3 0.035 
CYP3A5 *1 carriers *3/*3 2.24 0.13-39.7 0.290 
CYP3A4 rs35599367 T carriers CC 1.72 0.10-30.5 0.354 
MDR1 3435: CC CT or TT 3.00 0.74-12.2 0.107 






Interestingly in this cohort EBV seronegativity –the only well-recognized risk factor for 
PTLDs- at the time of KTx was not significantly associated with PTLDs (OR=4.70; 95%CI: 
0.536-41.3; p =0.125). 
As these SNPs act on CNI metabolism and a therapy with mTOR-i is being associated with 
less post-transplant virus-related malignancies, particularly NMSC and PTLD, we decided to 
focus our analysis on Caucasian patients who did receive a CNI, excluding few patients with a 
CNI-free immunosuppression. Indeed none of the patients who were on mTORi-MMF 
developed a PTLD (0/15, p: ns). The comparison between patients with a PTLD and those 
without was not able to identify any significant clinical risk factor. The associations of 
CYP3A5, TCF7L2 and MDR1 polymorphism were confirmed in this sub-population. 
 
Table – Comparison between pre-PTLD characteristics of patients who 






Male 75,0% 66,1% 0,56 
Age 57,9 ± 11,7 52,9 ± 12,4 0,13 
EBV seroneg. 12.5% 2.9% 0.09 
FK 100% 100% - 
mTORi 0% 0,5% 0,95 
MMF 87,5% 97,1% 0,23 
ATG 12,5% 11,5% 0,96 
BPAR 12,5% 8.3% 0,51 
6 mo Creat 1,70 ± 0,37 ± 0,65 0,30 






Therefore we were able to stratify the population by EBV serology, CYP3A5 haplotype, 
TCF7L2 rs7903146 and MDR1 C1236T genotype in the categories reported in table. Indeed some 
subgroups of patients had few or no patients, so we re-grouped these subgroups according to their 
PTLD risk. 
Table – Details of patients stratified by baseline risk factors and crude rate of PTLDs during 















*3/*3 Pos/miss CT or CC CT or CC 222 (53.5) 53.1±12.5 0 3.9±3.4 
*3/*3 Pos/miss CT or CC TT 88 (21.2) 52.5±12.2 4 (4.5) 4.3±3.7 
*3/*3 Pos/miss TT CT or CC 33 (8.0) 52.7±13.5 1 (3.0) 5.0±3.8 
*3/*3 Pos/miss TT TT 14 (3.4) 50.4±9.9 2 (14.3) 5.4±4.0 
*3/*3 Neg CT or CC CT or CC 6 (1.4) 43.7±16.9 1 (16.7) 5.5±4.6 
*3/*3 Neg CT or CC TT 3 (0.7) 49.8±6.3 0 8.4±6.4 
*3/*3 Neg TT CT or CC 1 (0.2) 72.4 0 5.1 
*3/*3 Neg TT TT 1 (0.2) 32.2 0 11.5 
*1 carr 
Pos/miss CT or CC CT or CC 22 (5.3) 52.9±11.8 0 4.2±4.2 
*1 carr 
Pos/miss CT or CC TT 19 (4.6) 50.3±14.2 0 4.7±4.2 
*1 carr 
Pos/miss TT CT or CC 5 (1.2) 56.3±9.8 0 4.0±2.7 
*1 carr 
Pos/miss TT TT 0 - - - 
*1 carr 
Neg CT or CC TT 1 (0.2) 48.7 0 9.5 
*1 carr 
Neg CT or CC CT or CC 0 - - - 
*1 carr 
Neg TT any 0 - - - 
 
From this data we can hypnotize that the CYP3A5 *1 haplotype has a protective role, while risk 
factors for PTLD are a negative EBV serology, TCF7L2 rs7903146 TT genotype and MDR1 
1236 TT genotype. Based on these definitions, we can define the a “low risk” group (n=269; 
64.8%) including patients carrying the “protective” CYP3A5 *1 haplotype (regardless of the 
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other risk factors, even if all patients had only one or none) or without any risk factor; an 
“intermediate risk” group (n=121; 29.2%) including patients with one genetic risk factor and a 
“high risk” group (n=25; 6.0%) including EBV-negative patients or those with both genetic 
risk factors. 
Indeed in “low risk” patients the mean PTLD incidence rate is 0 (95%CI: 0-3.34/100-pt-yr), 
while in “intermediate” and “high risk” patients it is respectively 9.15/100-pt-yr (95%CI: 2.95-
21.34) and 19.87/100-pt-yr (95%CI: 4.00-58.07). When considering this risk stratification in a 
multivariate Cox model for PTLD giving to each risk increase a score of +1, this risk 
stratification accurately predicts the outcome (Model A), with narrower confidence intervals as 
compared to a model including automatically-selected significant variables (Model B). The 
AUROC of model A was 0.891 (95%CI: 0.818-0.964) and of model B was 0.841 (95%CI: 0.730-
0.952), which are not statistically different, but model A seems to be more accurate. 
 
Figure: Kaplan-Meyer PTLD-free survival stratified by risk class: low risk (black line), 




Comparison between the Cox proportional hazard models: Model A includes 
risk classes (low risk = 0; intermediate = 1, high = 2); model B only includes 
selected variables (backwards stepwise). 
Model Variable HR 95%CI p 
A Age (per year) 1.083 1.011-1.160 0.024 
 Risk class 6.219 2.225-17.38 <0.001 
B Age (per year) 1.087 1.010-1.171 0.027 
 MDR1 1236: TT 7.190 1.392-37.14 0.019 
 TCF7L2 rs7903146 TT 4.658 1.035-20.97 0.045 
 
Comparison between the ROC curves of Model A (dashed line) and B (black line). Model 




PTLD: case-cohort study 
Specific Aims: To identify risk factors and clinical biomarkers of PTLDs. 
Overall, 49 PTLD index cases were identified in 9 transplant centers, to which 196 controls 
were matched. The mean index time (defined for each case-controls group as the time from 
KTx to PTLD occurrence) was 104±65 months: only 142 controls (2.90/case) reached the 
index time of their corresponding case. 
The PTLD cases belonged to different clinic-histological categories, ranging from early 
lesions, to leukemia. Most of them were EBV positive, ie: EBV replication could be detected 
within pathologic tissue. However in most cases (29/49=59.2%) this evaluation was missing 
and could not be recovered. 
 
PTLD Pathology of included cases 
Early Lesion 2 (4.1%) 
Polymorphic Lymphoma 3 (6.1%) 
B cell Monomorphic Lymphoma 32 (65.3%) 
        Large B Cell Diffuse Lymphoma 28 (57.1%) 
T cell Monomorphic Lymphoma 4 (8.2%) 
Hodgkin disease 4 (8.2%) 
Large granula lymphocyte leukemia 1 (2.0%) 
Unspecified 2 (4.1%) 
EBV-replication within PTLD 
14/20 
(70%) 





Each case was matched to four control KTR at the time of transplantation (case-cohort study) 
by age (± 5 years), sex, transplant center, year of transplantation (±2 years) and transplanted 
organ (living vs. deceased donor). Matching was maintained more “free” as compared to the 
original study design, but still cases and controls had a good matching for the matching 
variables. 
At baseline there were no significant differences between PTLD cases and controls.  
 








Female 24,5% 25,0% 0,941 
Age at KTx 42.0 ± 14.6 42.6 ± 13.6 0,814 
Year of KTx 1999 ± 5.9 1999 ± 5.8 0.952 
Living donor 10.2% 4.6% 0.130 
Center matching Confirmed in every control 
 







ATG   7/49 (14.3%) 29/192 (15.1%)  
 
0,783 
Ab anti IL2R 19/49 (38.8%) 63/192 (32.8%) 
No induction 23/49 (46.9%) 100/192 (52.1%)) 
Tacrolimus 19/49 (38.8%) 59/193 (31.6%) 0,253 
MMF 20/49 (40,8%) 75/192 (40,3%) 0,792 
m-TOR inib.   3/49 (6,7%) 18/196 (10,3%) 0,457 
Initial IS drugs 2.65 ± 0.52 2.66 ± 0.51 0.918 
CMV Serology (neg) 10/45 (22.2%) 37/169 (21.9%) 0.571 
EBV serology (neg) 14/40 (35%) 26/114 (22.8%) 0.130 





EBV serology was not a significant risk factor for PTLDs overall (OR=1.822; 95%CI: 0.833-
3.989; p=0.130), but EBV-related PTLDs showed a stronger trend towards being more 
common in EBV negative patients (OR = 2.567; 95%CI: 0.762-8.650; p=0.066) than EBV-
unrelated PTLDs (OR of EBV negative = 1.415; 95%CI: 0.500-4.011; p=0.299). 
Moreover, there was an unexpected interaction between EBV serology and ATG induction 
(lymphocyto-toxic): EBV negative patients who received ATG had a PTLD risk similar to the 
one of EBV positive patients (OR=0.971; 95%CI: 0.110-8.57; p>0.90), while EBV negative 
patients who did not receive ATG had an increased risk of PTLD as compared to EBV positive 
patients (OR=3.01; 95%CI: 1.381-6.560; p=0.004). Interestingly, among EBV-positive 
patients, the use of ATG was not associated with an increased risk of PTLD (OR=1.146; 
95%CI: 0.432-3.037; p=0.785). 
During follow up, data on therapy were available in all patients at one year and in most patients 
following the first post-transplant year: pharmacokinetic parameters have been calculated on 
these data. Interestingly no major differences could be noted for these parameters between 
cases and controls. 
Table – Follow up characteristics of cases (PTLD) and matched controls 
 Cases Controls p 
Dose CyA follow up (mg/die) 226±52,2 212,1±62,7 0,28 
Dose CyA f. up (mg/Kg/die) 3,43±0,88 3,29±1 0,51 
C0 CyA f. up (ng/mL) 167,3±42,8 164,8±54 0,621 
Dose FK f. up (mg/die) 5,1±2,8 5,3±2,3 0,695 
Dose FK f. up (mg/Kg/die) 0,076±0,037 0,084±0,043 0,429 
BTL FK follow up (ng/mL) 8,26±1,98 8,26±3,33 0,89 
Dose MMF follow up (mg/die) 1119±388 1226±438 0,293 
Dose AZA follow up (mg/die) 59,3±12 75,7±25,8 0,038 
Dose Steroid f. up (mg/die) 6,3±2,5 6,1±2,2 0,532 
Dose mTORi f. up (mg/die) 1,54±1,27 2,18±0,94 0,133 
CoV Cyclosporine (%) 32,3±15,4 33,8±15,6 0,912 
CoV FK (%) 32,7±19,9 27,1±10,6 0,107 
CoV dei CNI (%) 32,6±17,5 31,4±14,3 0,262 
DnTL CyA 53±19,6 54,4±25,6 0,788 
DnTL FK 140,8±89,3 121,2±65,2 0,282 
CoV: intrandividual coeficient of variability (on at least three BTL values; equals to st.dev(BTLi)/mean(BTLi) 
DnTL: dose normalized trough level, calculated as BTL divided by weight-normalized drug daily dose 
Cya: Cyclosporine; FK: Tacrolimus; CNI: CyA or FK; BTL: blood through level; C0: pre-assumption drug level. 
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However, we noted that patients on high doses of CNI were more likely to develop a PTLD 
(OR=2.890; 95%CI: 1.455-5.740; p = 0.002). A “High dose” of CNI was defined as a CNI 
dose greater than the median daily dose of the entire cohort, being a tacrolimus dose greater 
than 0.075 mg/Kg/day or a cyclosporine dose greater than 3.25 mg/Kg/day. Interestingly this 
variable interacted significantly (p=0.029) with EBV serology at the time of KTx. Particularly 
high dose CNI increased the risk only in EBV-negative patients (OR=3.451; 95%CI=0.811-
14.67), but not in EBV-postive patients (OR=1.818; 95%CI=0.788-4.195). 
 
Table - Crude PTLD rate in different subgroups of patients, stratified by CNI 








11 / 20 
(55,0%) 
11 / 53 
(20,8%) 
22 / 73 
(30,1%) 
Low 
3 / 19 
(15,8%) 
17 / 135 
(12,6%) 
20 / 154 
(13,0%) 
Total 
14 / 39 
(35,9%) 
28 / 188 
(14,9%) 
42 / 227 
(18,5%) 
 
Table – Five-years OR of PTLD in different subgroups of 
patients, stratified by CNI dose and EBV serology at KTx, as 
compared to EBV+ patients receiving low dose CNI 


















HPV and NMSC 
Specific Aims: to evaluate the role of active HPV on NMSC development in KTRs. 
In a first step (2012-2014), our gourp analyzed 111 FFPE blocks obtained from 79 skin lesions 
of 17 patients from our cohort of KTRs for the presence of active HPV infection by anti-E4 
and anti-L1 staining. Areas with E4-positive cells were found in 6 FFPE blocks from 4 patients 
that corresponded to 4 precancerous actinic keratosis (AK) lesions and the adjacent 
pathological area of a SCC and a BCC. Since then, 97 additional FFPE blocks from 70 skin 
lesions excised from 21 patients have been analyzed following the same procedure. Within this 
second group, an interesting case emerged of a female KTR who was evaluated for a second 
transplant due to the failure of her first graft after 25 years. Indeed, this new round of 
investigation allowed us to identify 3 additional blocks with βHPV-positive areas that were all 
derived from this case.  
Her long clinical history reported the development of many proliferative skin lesions in different 
body sites, starting approximately 10 years after the first KTx. Fifteen FFPE blocks 
corresponding to the excised tumors from this patient were available that were diagnosed as SCC 
(n=7), BCC (n=4), and keratoacanthoma (KA) (n=4). E4-positive areas were found in 2 KA 
located on the leg and the pathological hyperplastic border of an SCC located on the hand. As 
expected for HPV infected tissues, E4 positive cells were clearly evident in the areas of the lesion 
with hyperkeratosis and parakeratosis; some of them were trapped in the keratin layers where 
L1-positive nuclei were also observed. The cellular proliferation marker MCM7 was more 
evident in the E4-positive area compared with the adjacent epithelium, and was most apparent 
in the basal and suprabasal layers, indicating that cells were stimulated to enter the cell cycle. 
This increase in MCM7 expression was even higher in the adjacent pathological epithelium of a 




Figure - Clinical and histological findings from the skin of a KTR patient with 25 years of 
immunosuppression. Flat whitish and reddish papular lesions on the forearm (left) and 
crusty/erythematous lesions on the hand (Panel A).  Detection of the HPV E4 and L1 proteins, 
or cellular minichromosome maintenance protein 7 (MCM7) in a keratoacanthoma (KA, leg) 
(Panel B). The top picture shows hematoxylin and eosin (H&E) staining in the tissue section 
(scale bar: 1000 m). The region shown in the lower panels corresponds to the blue square 
highlighted in the overall H&E image, magnified in the left-hand lower panel. In the middle 
picture, the same section was subjected to double staining using antibodies to E4 (green) and 
MCM7 (red) (middle picture), and a serial section was stained with antibodies to L1 (red) and 
E4 (green)(right picture). The white arrows indicate nuclear L1 staining. All sections were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue) to visualize cell nuclei. Scale 





Figure - Immunohistochemical staining for the HPV E4 and L1 proteins, or cellular 
minichromosome maintenance protein 7 (MCM7) in a basal cell carcinoma (BCC) located 
on the neck of a KTR. The top picture shows hematoxylin and eosin (H&E) staining of the 
tissue section (scale bar: 1000 m). The red square shows the basal cell carcinoma and the blue 
square indicates the area of interest in the adjacent epithelium. The region shown in the lower 
panels  corresponds to the blue square highlighted in the overall H&E image, magnified in the 
left-hand lower panel. In the middle picture, the same section was subjected to double staining 
using antibodies to E4 (green) and MCM7 (red), and a serial section was stained with antibodies 
to L1 (red) (right picture). The white arrow indicates nuclear L1 staining. All sections were 
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue) to visualize cell nuclei. Scale 
bars: 100 m. 
 
 
As “positive control”, we included 12 patients who developed genital cancer. Among these, 4 
were vaginal and vulvar intraepithelial carcinoma, usually rare in the general population. 
Another intriguing observation is that 3 of them suffered from graft pyelonephritis that 
constitutes a rare infective complication in the general KTR population (<5%). Staining with 
anti-HPVE4 of the VAIN from patient 9, diagnosed as grade 1 and 2, revealed high expression 
levels of E4 in the differentiating superficial layers, with small patchy negative areas, where p16 
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expression appeared in some of them. As expected for a low-grade productive lesion, the late 
protein L1 was clearly evident in the nuclei of the more superficial layers. Routine testing for 
HPV revealed its presence in nearly all lesions; all concerning high-risk genotypes and often 
presenting multiple infections (data not tabulated). 





Tx Date Lesion Notes 
1F 1961 2004 2008: Hysterectomy (CIN1, 2)  
2F 1954 2009 
2010: Hysterectomy (atypical     
          hyperplasia of endometrium) 
2009: CMV reactivation 
3M 1955 2005 
2009: Condilomas  
 
2009: BCC shoulder  
4F 1945 2001 
2006: Atypical hyperplasia of cervix  
 
2005: Acute pyelonephritis (graft) 2005: CMV 
reactivation 
5F 1962 2006 
2009: VAIN2  
2010: Vaginal, cervical koilocytosis  
 
2006-2015: Multiple UTI  
2012: Pyelonephritis with abscess (graft) 
6F 1969 2006 
2007: CIN2  
2011: CIN1  
 
2007: PyVAN 
2011: Graft RCC 
7F 1966 2011 
2009: Esocervix metaplasia  
2012: CIN1, 2  
 
 
8F 1952 2009 
2010: VAIN1  
 
 
9F 1948 1999 
2003: VIN2  
2003: CIN1  
2004: Hysterectomy (CIN1, 2, 3)  
2005: VAIN1, 2  
 
1999-2015: Multiple UTI 
10F 1968 2001 
2006: Atypical, high grade     
          dysplasia on plain condiloma  
 
 
11F 1959 2000 
2003: CIN3  
 
2002: Acute pyelonephritis (graft)  
2004: Acute pyelonephritis (graft) 
12F 1967 2006 
2007: CIN2  
2007: CIN3 
2008-2014: positive BK-viruria 
KTx:  Kidney  transplantation;  CIN:  Cervical  intraepithelial  neoplasia;  VIN:  Vaginal  intraepithelial  neoplasia,  VIN:  Vulvar  intraepithelial  
neoplasia,  CMV: Cytomegalovirus; BCC: Basal cell carcinoma; UTI: Urinary tract infection; PyVAN: Polyomavirus-associated nephropathy; 
RCC: Renal cell carcinoma; BKPyV: BK virus. 
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Figure - Immunohistochemical staining for the HPV E4 and L1 proteins, or cellular 
minichromosome maintenance protein 7 (MCM7) and p16 INK4a in a vaginal intraepithelial 
neoplasia (VAIN) from patient 9 of Table 1S. The top pictures (scale bar: 1000 m) show the 
hematoxylin and eosin (H&E) staining of the tissue section (left) and the same section following 
double staining using antibodies raised against E4 (green) and MCM7 (red). The region shown 
in the lower panels corresponds to the blue square highlighted in the overall H&E image and to 
the red square in the picture of the E4-MCM7 staining (first and second pictures). A serial section 
was stained with antibodies to L1 (red) (third picture). The white arrows indicate nuclear L1 
staining. All sections were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue) to 
visualize cell nuclei. The fourth picture shows a serial section stained for the cellular protein 
p16INK4a by means of immune-enzymatic staining. This section was counterstained with 




BKV and urinary tract malignancies 
Specific Aims: To evaluate the role of active HPyV or BKV-associated nephropathy on the 
development of tumors of the urinary tract in KTRs. 
In the study cohort, 13 urinary tract malignancies arose in 13 KTRs as follows: 8 renal 
carcinomas in the native kidney and 2 in the transplanted kidney, and 3 carcinomas of the 
bladder (Table). Three of these patients (23.1%) experienced a PyV-associated nephropathy 
(PyVAN, polyomavirus-associated nephropathy) before cancer diagnosis, while none had a 
PyVAN after cancer development. Interestingly, the percentage of patients with urinary tract 
cancer for whom a diagnosis of PyVAN was reported before the development of this 
malignancy was significantly higher (3/16; 18.75%) in comparison with those who never 
experienced PyVAN (10/1024; 0.98%).  
 
Figure. Cumulative incidence of urinary tract malignancies (renal cell carcinoma or 
bladder carcinoma), stratified by a time-varying indicator of diagnosis of a PyVAN. Death 
and graft failure were considered as competing events. HR = 23.9 (95%CI: 6.02-95.2; p < 












1M 1952 2008 2010: Clear cell RCC FG 2 T1a 
2010: Graft failure /Second Transplant 
2010: Acute promyelocitic leukemia 
2M 1969 2008 2010: Clear cell RCC  FG 3  T1b  
3M 1948 2003 
2004: Clear cell intracapsular 
RCC FG 2 
T1a 2003: Graft failure 
4M 1954 2008 2008: Papillary RCC FG 2 T1a  
5F 1969 2006 2011: Clear cell RCC (KTx) T3a N0 
2007; 2011: CIN (Pt 6 Table 1S) 
2007: PVAN 
6M 1965 2005 2006: Clear cell RCC FG 3  T1a 2011: Acute HBV infection 
7M 1954 2007 2009: Clear cell RCC FG 2  T3a 2009: Graft failure 
8M 1969 2001 2007: Clear cell RCC  FG 2  T1a 2006: Viral enteritis 
9M 1949 2003 2004: Clear cell RCC FG 2  T1a 
2004: PVAN (cause of graft failure) 
2010: Death 
10M 1942 2006 2006: Clear cell RCC  FG 2  T1a 
2006: Pneumonia; CMV reactivation 
2006: Death 
11M 1948 2000 
2010: LG Bladder 
urothelioma 
Ta 
2001: CMV disease (hematological) 
2002: AK; VZV reactivation 
2006: SCC; AK (neck) 
2007: MGUS IgG-k (plasmacells at BMB: 5%) 
2014: Sepsis 
12M 1940 2001 
2001: LG In situ transitional 
carcinoma 
 
2005: Prostate cancer (Gleason 4) 
2009: Graft failure 
13M 1954 2000 




2010: Early tumor relapse (Ta) 
KTx: Kidney transplantation; RCC: Renal cell carcinoma; FG: Fuhrmann grade; CIN: Cervical intraepithelial neoplasia; PVAN: 
Polyomavirus-associated nephropathy; HBV: Hepatitis B virus; CMV: Cytomegalovirus; SCC: Squamous cell carcinoma; AK: Actinic keratosis; 





These epidemiological associations led us to investigate whether it was possible to detect 
HPyV infection/reactivation in the tumor mass or surrounding non-pathological tissues from 
the surgical specimens. To this regard, tissue sections from the available FFPE blocks 
(including blocks presenting the tumor core as well as those presenting non-neoplastic areas, 
such as the renal pelvis and ureter) were stained with anti-large T antibodies (pan-
polyomavirus antigen) by immunohistochemistry. Staining was only detected in patient 9, who 
underwent nephrectomy for RCC 3 weeks after the diagnosis of PyVAN. Consistent with the 
SV40-positive staining observed for the routine diagnosis of PyVAN (data not shown), 
numerous large T-positive cells were found in the urothelium lying the ureter, while the tumor 
cells were negative. FISH analysis was performed using the BKPyV genome as a probe, since 
genotyping of a urinary sample performed at the time of PyVAN diagnosis revealed the 
presence of BKPyV. A very strong nuclear signal overlapped the large T staining, indicating 
viral genome amplification in these urothelial cells. 
Out of the 3 urinary bladder carcinomas, only one turned out to be positive for the anti-large T-
antigen staining. This patient had a documented PyVAN 9 years before the onset of the bladder 
carcinoma in 2001. The majority of the tumor cells from this moderately differentiated 
carcinoma displayed a very strong staining for the large T antigen. By contrast the FISH signal 
with the BKPyV genome (BKPyV II genotype was found in the urine at the time of PyVAN) 
was less evident and mostly in the more superficial cells. Consistent with the observed 
dysregulated expression of the large T antigen in dysplastic cells, sustained p16INK4a 
expression was also found. Since this carcinoma quickly relapsed after endoscopic removal, a 
decision was made to change his IS therapy from tacrolimus-steroids to sirolimus-steroids. At 
the time of the patient’s last follow up visit (in December 2015), he was still being treated with 
sirolimus and steroid and there was no sign of urinary tract malignancy, although low levels of 




Detection of polyomavirus large T antigen and BKPyV DNA in the ureter of the native 
kidney removed for a clear cell carcinoma from patient 9 of Table 2S. The left picture shows 
the scan of the tissue section stained for the large T antigen (scale bar: 1000 m). The region 
shown in the middle picture corresponds to the blue square highlighted in the left image (scale 
bar: 100 m). This section was counterstained with hematoxylin to visualize cell nuclei. The 
right picture shows a serial section stained for the presence of the BKPyV genome by fluorescent 
in situ hybridization (FISH) (red) (inset: magnification of the white square). The white arrows 
indicate FISH-BKPyV positive nuclei. This section was counterstained with 4’,6-diamidino-2-







Detection of polyomavirus large T antigen, BKPyV DNA, and the cellular protein  p16 INK4a 
in the urinary bladder carcinoma from patient 13 of Table 2S. Left picture shows the scan 
of the tissue section stained for the Large T antigen (scale bar: 100 m). Right picture shows the 
scan of a serial section stained for p16INK4a (scale bar: 100 m). This section was counterstained 
with hematoxylin to visualize cell nuclei. The middle picture shows a serial section stained for 
the presence of the BKPyV genome by fluorescent in situ hybridization (FISH) (red) (scale bar: 
100 m). The regions shown in the insets correspond to the red and blue squares (scale bar: 10 
m) This section was counterstained with 4’,6-diamidino-2-phenylindole (DAPI) (blue) to 






This work on long term kidney transplant complications was divided into different sub-studies: 
indeed, long term complications are the major issue of current clinical transplantation and a 
“personalization” of therapy is an unmet clinical need in this field. The most common (and life-
threatening) complications are post-transplant vascular events and malignancies. 
Still, personalization in transplant medicine is an intriguing choice: we can choose among at 
least four classes of immunosuppressants (CNI, mTORi, antimetabolites, steroids) and novel 
therapies are being developed and implemented (“chronic” induction, anti-immunoglobulin 
therapies, anti-citokine therapies). Moreover, trials on single “non-immunosuppressant” drugs 
(like statins, ACEi. ARBs) have shown inconsistent results, probably because the “transplant 
mileau” is different from the general population and because the same events might have a 
different pathogenesis in KTRs than in the general population. Lastly, “over-the-counter” drugs 
(like vitamin D) and life habits changes are being widely prescribed, but without solid proofs 
of their efficacy or safety: given that there is a strong rationale to adopt these drugs/measures, 
the doses might be very different in KTRs due to the interaction with IS and the residual CKD. 
This thesis was performed with the aim to find some “cornerstones” which may be able to 
guide clinical practice and future research: the first step of modern “personalized medicine” is 
to develop risk stratification tools for hard endpoints. Then, we will be able to identify among 
non-reponders the causes/pathways of a reduced response and act on them specifically. Indeed, 
personalization of medicine is the personalization of care based on measurable patient’s 
genetics, molecular or cellular analyses: therefore, diagnostic testing is not performed to 
“diagnose” a pathological condition, but rather to guide therapy, such as drug monitoring was 
proposed several decades ago, which was very effective on short-term outcomes, but yet is not 
able to accurately predict long term complications. 
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Which gene variants are useful? 
We have investigated five SNPs which were previously associated with post-transplant 
complications, including two SNPs affecting IS metabolism (CYP3A5 *1, CYP3A4 
rs35599367), two SNPs of the MDR1 affecting IS biological effect (rs1045642 and rs1128503) 
and a SNP affecting “induced” inflammation, apoptosis and fibrosis (TCF7L2 rs7903146). 
Indeed for specific endpoints there might be more and different genetic variants: for example 
there are about 30 variants which have been associated with the risk of acute rejection and 
almost 20 SNPs affecting cardiovascular risk, but with inconclusive and conflicting results in 
different populations. 
CYP3A4 rs35599367 was not found associated with any of the investigated endpoints. This is 
consistent with previous reports showing an association with “acute”, peak-dependent side 
effects, particularly for cyclosporine, such as a delayed graft function (doi: 
10.1097/FPC.0b013e328351f3c1). Indeed tacrolimus pharmacokinetics is affected by this 
variant, having T carriers a 33% lower BTL than CC homozygous (doi: 
10.1373/clinchem.2011.165613), which could be translated to a 30-40% higher dose 
normalized through level. Even if it seems a large change in pharmacokinetics it is much 
smaller than the one associated with the CYP3A5 *1 genotype, which induces a an increase in 
the DnTL of about 100% (doi: 10.1016/j.transproceed.2013.11.084). 
Moreover the prevalence of T carriers in the white caucasian population of European ancestry 
is relatively small, with a minimum allele frequency of 0.0497: indeed, in our cohort it was 
10.1% in white caucasians. As for power calculation, we could expect that we would be able to 
detect an OR of at least 5.5 (5% alpha error, 20% beta error), and such a large OR is unlikely to 




CYP3A5 *1 genotype carriers were found to be less likely to develop a virus-related 
malignancy, particularly we focused our analyses on PTLDs. 
This haplotype is relatively uncommon in western European patients, ranging between 10% 
and 15% (in our cohort it was 12.2%), while it is more common in Asian patients (up to 30%-
35%). This polymorphism has been associated with high CNI requirements (tacrolimus daily 
dose > 0.1 mg/Kg, DnTL < 100 ng*Kg/(mL*mg)) and a relatively low drug exposure (doi: 
10.1097/FPC.0b013e3283557c74). Indeed, even if DnTL could be a useful marker of the AUC 
of tacrolimus levels, genetic predisposition can be known before KTx and preventive measures 
could be implemented early after transplantation. In a previous paper by our group, CYP3A5 *1 
carriers had a higher risk to be “fast metabolizers” (doi: 10.1007/s00228-011-1150-0), and 
actually had less infections. Interesting the rate of CMV reactivation in our cohort was much 
higher rate in *3/*3 patients, regardless of CMV serostatus at the time of transplantation. 
These observations are consistent with a “zero-rate” of virus-associated malignancies in 
CYP3A5 *1 carriers, confirming that patients with higher drug requirements may indeed suffer 
from less infective complications given a target BTL. As shown for CMV -for which 
surveillance programs are standard clinical care- a reduced rate of EBV reactivation could be 
the reason why we did not observe any PTLD among *1 carriers. 
Interestingly non-immunological events, like PTDM and CAD, had a similar incidence in 
CYP3A5 *1 carriers and *3/*3: no simple explanation can be given, however, as PTDM was 
not associated with tacrolimus levels, we could speculate that the effects on glucose 
metabolism are not dose dependent within therapeutic range. 
Knowing this genetic variant before transplantation may indeed help clinicians in different 
settings: first the CNI dose in the first post-transplant days could be better defined, as up-to-
date guidelines only recommend a weight-normalized daily dose, exposing *1 carriers to be 
under-immunosuppressed in the very first days after transplantation. Indeed, during these days 
donor’s antigens are widely exposed and -as CNIs mainly inhibit the response to unknown 
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antigens- these are the days in which an “on target” IS may be helpful in reducing long-term 
immunization. Moreover, patients with a high immunological risk and a *1 CYP3A5 could be 
maintained on higher BTL without exposing them to a significantly increased risk of infections 
or malignancies. Lastly, theoretically, screening for virus-induced malignancies (genital, 
PTLD, NMSC, kidney and urinary tract) and common viral reactivations (CMV, BKV) could 
be less intense in CYP3A5 *1 patients. 
 
MDR1 rs1045642 and rs1128503 were strictly correlated (concordance > 80%) and even if 
some associations were more evident for rs1128503, they were present for rs1045642 too. The 
most interesting association is between rs1128503 TT genotype and PTLD risk: this variant has 
not been associated with different CNI pharmacokinetic profiles (doi: 10.2217/pgs.11.70; 
PMID: 16415525), but with several drug side effects (doi: 10.1097/MD.0000000000001315). 
Indeed, p-glycoprotein (PgP), the transcript of MDR1, is expressed in almost every cell, 
particularly on enterocytes (luminal side), kidney tubule, liver, endothelium, neurons and 
gonads, both on cell membrane and on intra-cellular membranes. As it is an efflux pump, its 
role on drug pharmacokinetics is well understood: a more efficient PgP reduces drug 
absorption (the drug is secreted in the intestinal lumen) and favors the renal and biliary 
clearance of the drug and its metabolites. Thus, MDR1 polymorphisms affect mainly drugs 
with a highly variable drug absorption and with a mainly renal clearance, like digoxin (PMID: 
12698307), but not CNIs and steroids. 
On the other side, the effects of MRD1 polymorphisms on drug pharmakodynamics have not 
been extensively studied in “physiological” settings, but mainly in malignant tissues. Some 
data are available on drug distribution to different tissues, but the effects on the intracellular 
drug distribution and effects are lacking. Therefore we cannot directly predict which will be the 
consequences of slow and fast transporters on the overall drug effects: epidemiological data are 
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consistent with the hypothesis supporting that slow transporters (ie patients with the TT 
genotype) might have more “drug effects” on PgP-expressing tissues (PMID: 12831320). 
Nevertheless, in the Novara cohort slow transporters (rs1128503 TT) had an increased risk of a 
long-term, virus-related complication: PTLDs. We could speculate that these patients had a 
greater drug absorption and reduced clearance, but this does not seem the case in our cohort, 
confirming literature data on the effect of this SNV on CNI pharmacokinetics (PMID: 
14517192). However a longer intracellular CNI persistence may have had two effects: on the 
one side it might have inhibited more the anti-viral immune response, and the other hand it 
may have reduced the activation-dependent apoptosis of B cells. Therefore, given that 
activation induces PgP expression on lymphocytes (PMID: 10773966), MDR1 variants could 
explain some CNI effects on activated lymphocytes even if they do not alter their 
pharmacokinetics. Indeed, in the Parma case-cohort study, we were not able to identify any 
single therapy-related risk factor for PTLDs even if the study power was adequate to find risk 
factors associated with an OR of 2 or more. 
The observed association (slow PgP with PTLD) may thus be explained by a higher 
susceptibility to chronic, subclinical activation of EBV because these patients have a slower 
viral clearance. However in this work we did not monitor EBV reactivation and its duration, so 
we are not able to confirm this hypothesis. Moreover they are more likely to fail to “shut off” 
immune response (slower activation-dependent apoptosis) and therefore be more likely to 
acquire mutations inducing malignant diseases. Future studies could be aimed to confirm or 
confute these hypothesis, for example with periodic EBV viremia measurements and with “ex 






TCF7L2 rs7903146 was confirmed as an optimal marker for PTDM and it was tested also for 
CAD and PTLDs. 
TCF7L2 rs7903146 T variant was found to confer a higher risk of PTDM in an allele dose-
dependent manner in our cohort and the pooled analysis of the present data with those of 
previously published studies provide evidence of strong association between rs7903146 TT 
genotype and risk of PTDM in KTRs. Furthermore, it appears to improve risk stratification for 
PTDM when added into a model including the main relevant clinical variables. Taken together 
these findings yield new insights into the genetic conditioning of PTDM and suggests the 
possibility of predictive models of PTDM integrating clinical and genetic factors. 
The association of rs7903146 with PTDM is biologically plausible given that most 
immunosuppressive drugs (tacrolimus, steroids and mTOR inhibitors) both promote the 
apoptosis of pancreatic beta-cells and increase insulin resistance. However recent data support 
the hypothesis that impaired insulin secretion plays a greater role in PTDM than in T2DM (doi: 
10.1093/ndt/gfs583): consequently, genes involved in beta-cell proliferation and apoptosis 
(such as TCF7L2) are excellent candidates to play a role in PTDM, probably to a larger extent 
than in T2DM. Therefore our results are consistent with the hypothesis that a genetically 
conditioned susceptibility to beta-cell dysfunction plays a significant role in the pathogenesis 
of long-term PTDM. Beta-cell dysfunction (affected by the interaction of environmental factors 
such as immunosuppressive drugs with genetic background) and the degree of insulin-
resistance both likely modulate the risk of this multifactorial condition. Consistently, 
multivariate analysis shows that TCF7L2 rs7903146 T allele significantly increases the risk of 
PTDM but other variables related to insulin-resistance, such as higher BMI and previous KTx, 
are even stronger risk factors. Further studies are needed to elucidate the relative contribution 




Moreover, TCF7L2 rs7903146 C>T polymorphism seems to be strongly and independently 
associated with post-transplant CAD in non-diabetic KTRs in an allele dose-dependent 
manner. These findings might provide new insight into the genetic conditioning of ischemic 
heart disease and suggest the possibility of including this SNP in risk stratification models for 
post-transplant CAD. 
The role of rs7903146 in modulating cardiovascular risk in the setting of KTx is biologically 
plausible and could be mediated by a wide range of mechanisms. TCF-4 transcription factor, 
encoded by TCF7L2, is involved in the pathway of NF-kB; a dysregulation of this axis can 
alter bone remodeling, a key process leading to coronary artery calcification (CAC), and 
promote vascular wall inflammation, oxidation and endothelial dysfunction, 
pathophysiological features which have usually already been active since moderate stages of 
CKD, long before KTx. TCF7L2 rs7903146 has actually been associated with isolated fasting 
hyperglycaemia (IFH) and isolated postprandial hyperglycaemia (IPH) (doi: 
10.1371/journal.pone.0071399), which may increase cardiovascular risk in carriers of TT 
genotype even without diabetes (PMID: 22820698). Repetitive glucose spikes have actually 
been demonstrated to accelerate atherosclerosis in experimental models, suggesting the 
possibility that TCF7L2 rs7903146 may represent a facet of a common genetic predisposition 
to both diabetes and CVD (doi: 10.1371/journal.pone.0016341). Unfortunately, as no 
information about postprandial glycemia was available, we were not able to investigate this 
correlation.  
Interestingly, we found a stronger association of the allele with CAD in KTRs than in the 
general population, as for PTDM. This increased strength of association could be explained by 
the fact that genetic predisposition can emerge more clearly in KTx setting due to a higher 
event rate caused by interaction of polymorphisms with transplant-specific environmental risk 




On this basis, can genetic analysis of rs7903146 be useful in clinical practice? 
To test this possibility, we elaborated and compared predictive models for PTDM and CAD 
based on TCF7L2 genotype and clinical variables. Our results showed that rs7903146 
significantly improved predictive ability of risk models based only upon clinical factors, 
suggesting that information on TCF7L2 genotype could be useful for identification of KTRs at 
higher risk of PTDM and CAD. For instance, the multivariate model including this SNP and 
the main relevant clinical variables seems to have a good predictive ability for post-transplant 
CAD (AUROC=0.790) and the inclusion of this polymorphism significantly improved the 
predictive ability of the clinical risk model in our cohort (delta AUROC: +0.112; p =0.003). 
Availability of this genetic information prior to surgery would have important consequences: 
patients could be preemptively informed about their risk of PTDM and its associated risks; 
steroid withdrawal could be considered in high-risk patients, trying to balance metabolic 
benefits with a potentially increased risk of rejection (doi: 10.1007/s00228-012-1292-8); early 
and intensive insulin therapy to control hyperglycemia could be implemented in the immediate 
post-operative phase to minimize glucotoxic effect on beta cells; dietary interventions and life-
style modifications aimed at reducing overweight could be aggressively carried out long before 
KTx.  
On the other hand, recommendations from a recent international consensus meeting actually do 
not support adaptation of immunosuppressive therapy with the aim of minimizing PTDM risk 
due to lack of sufficient evidence (doi: 10.1111/ajt.12850). Although these limits are true 
considering the general populations of KTx recipients as a whole, a better stratification of 
PTDM risk through genetic polymorphisms could help identify a subset of high-risk patients in 
whom preventive measures such as steroid-sparing could instead be justified. 
Moreover, the availability of a predictive model for CAD prior to KTx in non-diabetic patients 
would entail important consequences: high-risk patients could be identified even in the absence 
of diabetes and other traditional risk factors and could be preemptively informed about their 
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risk of developing a cardiac ischemic event after KTx. For example, the 5-years risk of 
developing a cardiac ischemic event in our cohort is as high as 9.2% in carriers of the 
rs7903146 TT genotype, which indeed cannot be neglected. Many crucial aspects of KTx 
management could be affected, including early steroid withdrawal, resumption of anti-
aggregant therapy immediately after KTx, aggressive use of insulin to control post-KTx 




Which “phenotype characterization” is helpful? 
Apart from genes, environmental factors may be the key determinants of some post-transplant 
complications. Some “external” factors are common to the general population, like already 
shown for PTDM and CAD, while other are peculiar of KTRs. However “discovering” a KTR-
specific risk factor may be interesting also for the general population: some risk factors which 
are more evident in the transplant setting may have a relevance also in immunocompetent 
patients. 
To identify immunosuppression-related risk factors we focused on complications that are more 
common in KTR than in the general population. Vascular events are a major cause of 
morbidity and mortality; however, there are many confounders, including the already existing 
vascular damage (related to the previous CKD), the extent of residual renal dysfunction and 
therapies, both IS and concomitant.  
On the other side, both infections and malignancies have a much higher incidence in KTRs: 
therefore, we focused mainly on virus-associated malignancies, using as “environmental 
factor” viral replication. Indeed, genetic predisposition could probably play a role, but, as 
shown by our  results, this does not seem the case, apart from PTLDs. 
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Antiaggregant and vascular events 
We investigated the role of antiaggregant (AAT) and anticoagulant (VKA) therapies on early 
CVE: our results suggest that neither pre-transplant AAT or VKA therapies “per se” or their 
suspension are associated with a higher risk of CVE.  
The main risk factor for early post-KTx CVEs are previous CVE, but not the use of AAT and 
its subsequent withdrawal. Interestingly enough, no associations were observed between CVE 
and any immunosuppressive drug. Resumption of AAT after KTx occurred in our Center after 
a longer time than the one reported by other groups [doi: 10.1111/j.1399-0012.2010.01293.x.], 
mainly because we considered AAT as a relative contraindication to kidney biopsy, a relatively 
common procedure in the first weeks after transplant. However the rate of major CVE during 
the first three months after transplant is in keep with data reported from literature [PMID: 
23050275] and this temporary therapy withdrawal might be considered safe. However, a 
cautious assessment of risk-benefit profile should be made in each patient as high-risk patients, 
such as those with previous CVE, may have an advantage in resuming secondary prophylaxis 
earlier. 
Unexpectedly we found that CVE are associated to cinacalcet use at transplantation, probably 
because patients on this drug have had a more severe and long-lasting hyperparathyroidism, 
potentially leading to a more diffuse vascular damage. Moreover cinacalcet discontinuation 
after KTx has been widely associated with a rebound of PTH and calcium: further studies 
evaluating the role of cinacalcet on KTx early outcomes would be recommended, for example 
comparing post-KTx outcomes of patients enrolled in large multicenter studies (ie: EVOLVE, 






Beta Papillomavirus and NMSC 
This study extended previous observations from our group on the presence of active HPV 
infection in skin tumors from KTRs through the detection of viral protein expression, including 
the E4 and L1 proteins (doi: 10.1038/modpathol.2013). In this new round of screening, we 
analyzed 70 skin tumors derived from 21 patients and found positive staining in 3 tumors that 
were all removed from the same patient. This female patient in question was exceptional in that 
she received her kidney transplant 25 years ago, and developed more than 15 skin cancers and 
multiple pre-malignant skin lesions. Consistent with her clinical picture revealing multiple 
actinic keratosis on her forehead and dorsum of the hands, HPV viral protein expression was 
observed in 3 skin tumors, corresponding to 2 KA and the pathological hyperplastic border of 
an SCC. The 2 KA were classified as benign proliferative lesions that, especially in the 
immunosuppressed setting, are considered to be at high risk of malignant progression. These 
results are fully consistent with our previous reports and strengthen the notion that HPV are 
actively replicating in the pathological skin of organ transplant recipients and can therefore 
cooperate with other carcinogenic agents, such as UVB, favoring skin cancer promotion and 
progression (doi:10.1016/j.virol.2015.02.004, doi:10.1016/j.ctrv.2013.08.005). This hypothesis 
is compatible with the proposed ‘hit-and-run’ mechanisms of carcinogenesis, with cutaneous 
HPV possibly being important for tumor initiation and progression, but not necessary for 
tumor maintenance. These assumptions can explain the low virus detection rates found in this 
kind of study. The observed stimulation of basal cell proliferation in the HPV-infected 
tissues is similar to the situation seen in HPV-associated neoplasia and may contribute to the 
transformation process without necessarily being maintained in the more advanced disease 
(doi: 10.1038/modpathol.2015.52).  
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HPV infection can be detected in cutaneous intraepidermal precursor lesions of KTR, 
although its presence is never maintained in more advanced disease states and thus more 
difficult to observe. 
 
BK virus and urinary tract malignancies 
Another form of cancer with an incidence rate known to be significantly increased in the KTR 
setting regards kidney and urinary tract tumors; their incidence in KTRs is 4 to 10 times higher 
than in the general population. Of note, urinary tract cancer was statistically more frequent in 
patients with a previous documented diagnosis of BKVAN in comparison with those who never 
experienced this virus-associated complication. Reactivation of polyomavirus is associated with 
allograft viral nephropathy through ascending infection in the renal tubules. Emerging evidence 
is also indicating a causal link between viral reactivation and urinary tract carcinogenesis or 
RCC. 
Although BKV in urothelial carcinoma is distinctly rare in the general population, a recent report 
from a large KTR cohort, together with case reports and small series in the literature, and data 
from a transgenic mouse model suggest a significant rate of HPyV positivity in this cancer, at 
least in the kidney transplant population (doi: 10.1111/ajt.13550, doi:10.1038/sj.bjc.6604711). 
In addition, Kenan et al. recently documented genomic integration of BKPyV in tumor cells 
associated with robust dysregulated large T antigen expression in a high-grade urothelial 
carcinoma arising in a renal allograft (doi: 10.1002/path.4584). In our kidney tumor series, we 
failed to detect any large T antigen expression by immunohistochemistry in the tumor cells, while 
very strong expression was found in the urothelium lining of the ureter in a patient who had 
undergone nephrectomy of the native kidney for RCC soon after diagnosis of BKVAN in the 
allograft kidney. The FISH signal in these cells was very strong with a diffuse pattern and the 
appearance of large dots, very much resembling sites of intense viral genome replication. In one 
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bladder carcinoma, very strong and homogeneous large T antigen expression was observed in 
the tumor mass of a moderately differentiated urothelial carcinoma. This uniform staining has 
also been reported in other tumor series (doi: 10.1111/ajt.13550) and together with the recent 
finding of integrated truncated BK virus in a renal tumor displaying uniform large T-antigen 
expression (doi: 10.1002/path.4584) indicates that deregulated large T antigen expression may 
be associated with the transformation process. Accordingly, p16INK4 was highly expressed as 
expected for virus-induced dysplastic cells (doi: 10.1111/ajt.13550). When we looked at the 
FISH signal with a BKPyV DNA probe, the proportion of positive nuclei was significantly lower 
compared with the homogeneous distribution of large T antigen staining. Experiments are in 
progress to demonstrate viral integration; however, the discrepancy between protein expression 
and the FISH signal may suggest that clonal expansion of the transformed cells has occurred in 
this case.  
Although the sample size in our series is still limited, our findings support the notion that the BK 
virus, in addition to entering a lytic life cycle, resulting in the loss of renal tubule cells in 
BKVAN, can enter a non-lytic life cycle accompanied by deregulated expression of the 
oncogenic large T antigen in transformed cells.  
 
EBV vs. Genes in PTLD 
We’ve put a lot of efforts in determining risk factors for PTLDs: they are a rare and lethal 
complication of KTx, with a disease-specific mortality rate up to 30%. Moreover its SIR is 
very high, particularly for large B cell Lymphoma (about 10) and some lesions are peculiar of 
KTRs, like early lesions, which are composed by oligoclonal EBV-infected malignant 
lymphocytes. EBV plays a major role in their pathogenesis, particularly in pediatric 
transplantation, in which a primary EBV infection is relatively common, and in PTLDs 
occurring within 2 years from transplantation. PTLDs of elderly patients with a long lasting 
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transplant are usually assumed to occur through other pathways, probably not strictly 
dependent on EBV replication. Even considering these confounders, PTLDs are a very 
intriguing complication for research purposes: they are probably the result of a close 
interaction between host immune system, immunosuppressive drugs, EBV and other oncogenic 
viruses (HHV8, possibly BKV and HHV6) and mutagens. 
To date risk factors on PTLD are not well defined and even recent “wide” registry studies (doi: 
10.1111/tri.12744) focus on epidemiological descriptions rather than inferential analyses, while 
the attention is shifting from PTLD occurrence to PTLD effects on patient and graft survival 
(doi: 10.1111/tri.12375). Indeed, there is a wide consensus on PTLD incidence being highest in 
the first year and after the tenth year form transplant with a bimodal distribution, and on EBV 
seronegativity as the main risk factor, with an HR varying from 5 to 20 (doi: 
10.1016/j.trim.2015.04.003). Moreover, different solid organ transplants (heart, lung, pancreas, 
kidney, liver) have a different risk for PTLDs, but obviously they cannot be considered a “risk 
factor”; still, it is interesting to note that the highest risk is in observed in transplants requiring 
the highest IS (thoracic organs) and lower in non-life saving transplants in which IS can be 
tapered more safely (kidney). 
We have analyzed two cohorts, the Novara-gene cohort and the Parma case-cohort study, 
which included long lasting transplants and both early and late PTLDs. Particularly in the 
Parma cohort we were able to determine the relationship of the PTLDs with EBV in 20 cases. 
Interestingly, in neither cohort EBV serostatus at the time of KTx was significantly associated 
with PTLDs, even if OR overlapped with literature data (Novara: OR=4.70; 95%CI: 0.536-
41.3; Parma: OR=1.822; 95%CI: 0.833-3.989). 
The interaction between EBV and IS therapies in determining PTLDs is particularly clear in 
the Parma study, which enrolled 49 cases and 196 matched controls. Indeed, EBV serology 
was an effect modifier of the relationship between lymphocyte depleting agents (ATG) and 
PTLD: there was no association with ATG in EBV positive patients, while they seemed to be 
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protective in EBV negative patients (OR=0.323; 95%CI: 0.034-3.083; p=0.307), but possibly 
due to patient selection bias. Truly, in the past the use of ATG was relatively uncommon in 
EBV negative patients due to an expected increase in PTLD risk and EBV negative patients 
who received ATG have been probably carefully selected. 
Moreover, a high daily CNI dose (above the cohort median, being tacrolimus > 0.075 mg/kg or 
cyclosporine > 3.25 mg/kg) was associated with an increased risk of PTLDs only in EBV 
negative patients (OR=3.451; 95%CI=0.811-14.67), but not in EBV positive patients 
(OR=1.818; 95%CI=0.788-4.195). This finding is consistent with the hypothesis by which a 
sustained viral replication is needed to induce a PTLD: EBV seronegative patients often 
develop a primary EBV infection, but if the patient is able to rapidly clear the virus (ie: is 
receiving a low dose IS) the relative risk of a PTLD is relatively low (1.30 in this study). 
Moreover, in EBV positive patients, “standard” drug monitoring is not an adequate marker of 
sustained EBV replication and therefore PTLD risk. However some EBV-positive patients may 
be at a higher risk of PTLD due to an increased IS biological effect due to an altered 
intracellular CNI clearance (ie: MDR1 “slow transporters”) or by a genetic predisposition that 
can be “triggered” by a subacute EBV infection (ie: TCF7L2 rs7903146 TT genotype). 
These factors were investigated in the Novara-gene cohort, and partially discussed in a 
previous paragraph (Which gene variants are useful?). The effect of TCF7L2 is possibly a 
direct effect on lymphocytes. Its product (Transcription Factor 4, TCF4) recognizes an 
Ephrussi-box ('E-box') binding site -a motif first identified in immunoglobulin enhancers. It is 
widely expressed and TCF7L2 has multiple alternatively spliced transcript variants that encode 
different proteins with still unknown properties. TCF4 in the adult is involved mainly in the 
pathways of cell terminal differentiation and apoptosis: the rs7903146 T allele (less TCF4 
function) has been associated with a “slower” differentiation of fibroblasts, yielding to 
increased collagen production, and to an increased apoptosis of pancreatic beta-cells after a 
sovra-maximal glucose stimulus (ie: glucotoxicity). Indeed, given the wide spectrum of TCFs 
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functions, a reduction in the activity of one of them may indeed produce very different 
biological effects in different cell population. We can speculate that B cells of patients with a 
less functional variant (ie: rs7903146 T allele) have a defective differentiation towards B 
memory and plasmacells, yielding eventually to a relatively less effective specific humoral 
response, including the “memory response” of EBV positive patients. Moreover, B cells might 
tend to remain for a longer time in lymphnodes during their centrocyte and centroblast 
differentiation stage (doi: 10.1073/pnas.1205299110): this is actually the most likely state to 
gather mutations yielding to malignant lymphoma (diffuse large B cell lymphoma, the most 
common in KTRs). 
Even if the observed genetic association are not completely explained by current knowledge, 
they may explain the reason why to date no single “therapy variable” has been strongly 
associated with PTLDs, like we observed in the Parma study. Certainly “more 
immunosuppressed” patients are at higher risk for virus-related malignancies (like heart 
transplant recipients), but in the current setting of KTx IS there are very few (if not none) 
severely IS patients. 
Moreover, the proposed risk model for PTLDs is definitely intriguing: it is able to stratify 
accurately the risk of PTLDs (AUROC=0.891) and is able to determine which patient is at high 
risk for EBV reactivation (EBV seronegative and MDR1 slow transporters), those at a high risk 
for PTLD “per se” (TCF7L2 low expressors) and those with both risk factors.  
How to manage these patients will be matter of study: patients with a higher risk of EBV 
reactivation could benefit from a therapy with mTORi or with a low dose CNI (as shown in the 
Parma study) or even with a prolonged valganciclovir prophylaxis. Patients at the highest risk 
of PTLD will probably benefit also from a dedicated screening program, which would be 
useless if applied to the entire KTR population. As far as we know this is the first reliable 
model (AUROC>0.80) predicting PTLDs: it may be worth testing a similar model in other IS 
population, like those with autoimmune diseases or long term cancer survivors. 
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Potential applications and conclusions 
The main results of this PhD program were risk stratification models for common transplant 
complications, which are an unmet need for the transplant community. The first application of 
these models could be pre-transplant screening and information: based on the variants of three 
genes (CYP3A5 haplotypes, MDR1 rs1128503 and TCF7L2 rs7903146) we could be able to 
reliably predict the individual risk of post-transplant diabetes, ischemic heat events and post-
transplant lymphomas. As these complications are potentially lethal or impact severely quality 
of life, patients at high risk should be correctly informed. 
Moreover pre-transplant screening for variations in these gene may enable physician to 
modulate IS therapy based on their predicted pharmacokinetics and risk of complications. 
Before advising for specific clinical choices, randomized control trials should test these 
hypothesis: for example, regarding diabetes, it is well known that tacrolimus acts mainly on 
beta cells, while it has a relatively low impact on insulin resistance, therefore it may be 
substituted by cyclosporine only in patients at high risk for diabetes due to beta-cell 
insufficiency (second transplant, TCF7L2 rs7903146 TT carriers), while other measures (like 
the use of euglycemic agents, as glucagon agonists-liraglutide- or glycosuric drugs-
empagliflozin) could be used in more “insulin resistant prone” patients (ie: obese, older 
patients). On vascular events, primary prophylaxis has not been tested in KTRs: however, in 
high risk patients (ie: TCF7L2 rs7903146 TT carriers, previous CVE or previous therapy with 
cinacalcet) it seems a feasible option and even an early start appears to be safe in our cohort 
(doi: 10.1007/s40620-015-0185-1). 
Regarding PTLDs, patients with a higher risk of EBV reactivation could benefit from a therapy 
with mTORi or with a low dose CNI (as shown in the Parma study) or even with a prolonged 
valganciclovir prophylaxis. Patients at the highest risk of PTLD will probably benefit also from 




Moreover after transplantation novel screening methods for virus-induced malignancies could 
be implemented based on our findings. The case for BKV is “historically” interesting: 
screening for BKVAN was first performed with urinary decoy cells, then viruria and viremia, 
and nowadays viremia is considered the standard screening for BKVAN. Indeed patients with a 
BKVAN were at a high risk for malignancies of the urinary tract: viruria, more than viremia, is 
an earlier marker of subclinical BKV replication in the bladder and its role as a predictor of 
urinary tract cancer should be investigated, possibly identifying those patients with a sustained 
bladder BKV replication regardless of BKVAN. These patients could be given 
chemoprophylaxis, for example with mTORi, or undergo a more strict screening program. 
Similarly for NMSC, a sustained beta-HPV replication is a favoring factor to accumulate 
mutations yielding to NMSC. A primary infection acquired during IS therapy is more likely to 
be sustained, even if subclinical, also because there are no specific anti-viral agents: a novel 
infection can be demonstrated by the appearance of a new anti-HPV antibody (ie: against a 
different serotype than before KTx). These patients could benefit from a maximal NMSC 
prophylaxis or from more accurate screening. Moreover patients with an active beta-HPV 
replication before KTx -even if it may be hard to measure- could receive an HPV vaccine 
before surgery: it has been reported that alpha-HPV vaccine may indeed improve diffuse warts 
and frequently relapsing NSMC. 
In conclusion, viruses, host, immune system and therapies strictly interact and determine 
transplant complications: in each patient the relative contribution of each factor may be very 
different. The aim of personalized medicine is to determine how much each risk factor 
increases the risk of a complication in each individual patient: the developed models have a 
good AUROC and are able to differentiate between different pathogenetic moments. Based on 
this knowledge, we will need first to confirm these models in other cohorts and then to test the 
“biologically plausible” therapy and screening “personalizations” in patients carrying similar 
characteristics. Indeed the way towards personalized medicine is still long and probably more 
tortuous than what we believed few years ago, but still worth pursuing. 
